Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:boron molecular entity
go back to main search page
Accession:CHEBI:22916 term browser browse the term
Synonyms:related_synonym: boron compounds;   boron molecular entities



show annotations for term's descendants           Sort by:
 
2-[4-[(E)-2-(6,8-dichloro-2-phenyl-2H-chromen-3-yl)ethenyl]phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Nphs1 NPHS1 adhesion molecule, nephrin increases expression ISO BD4 increases expression of Nphs1 mRNA in podocytes RGD PMID:22125642 RGD:40902998 NCBI chr 1:85,720,812...85,749,079
Ensembl chr 1:85,720,812...85,749,078
JBrowse link
G Synpo synaptopodin increases expression ISO BD4 increases expression of Synpo mRNA in podocytes RGD PMID:22125642 RGD:40902998 NCBI chr18:54,048,299...54,106,388
Ensembl chr18:54,026,152...54,102,126
JBrowse link
2-aminoethoxydiphenylborane term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Bax BCL2 associated X, apoptosis regulator multiple interactions EXP 2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in increased expression of BAX protein] CTD PMID:29883672 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions EXP 2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in decreased expression of BCL2 protein] CTD PMID:29883672 NCBI chr13:22,689,783...22,853,920 JBrowse link
G Casp12 caspase 12 multiple interactions EXP 2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in increased cleavage of CASP12 protein] CTD PMID:29883672 NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
JBrowse link
G Casp3 caspase 3 multiple interactions EXP 2-aminoethoxydiphenylborane inhibits the reaction [cadmium acetate results in increased cleavage of CASP3 protein] CTD PMID:29883672 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Cd28 Cd28 molecule multiple interactions ISO 2-aminoethoxydiphenylborane inhibits the reaction [CD28 protein results in increased abundance of Calcium]; 2-aminoethoxydiphenylborane inhibits the reaction [CD28 protein results in increased abundance of Nitric Oxide]; 2-aminoethoxydiphenylborane inhibits the reaction [CD28 protein results in increased abundance of Reactive Oxygen Species] CTD PMID:14607919 NCBI chr 9:62,166,324...62,194,674
Ensembl chr 9:62,166,192...62,194,685
JBrowse link
G Grm1 glutamate metabotropic receptor 1 multiple interactions EXP 2-aminoethoxydiphenylborane inhibits the reaction [3,5-dihydroxyphenylglycine results in increased activity of GRM1 protein] CTD PMID:14622174 NCBI chr 1:5,058,285...5,453,170
Ensembl chr 1:5,058,292...5,453,170
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 multiple interactions ISO 2-aminoethoxydiphenylborane inhibits the reaction [bisphenol A results in increased expression of NFE2L2 protein] CTD PMID:33408296 NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
4,4-difluoro-4-bora-3a,4a-diaza-s-indacene term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 affects transport ISO ABCB11 protein affects the transport of 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene CTD PMID:12739759 NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
JBrowse link
boric acid term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ace angiotensin I converting enzyme multiple interactions ISO boric acid inhibits the reaction [epigallocatechin gallate results in decreased activity of ACE protein] CTD PMID:28544013 NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
JBrowse link
G Acta2 actin alpha 2, smooth muscle decreases expression ISO boric acid results in decreased expression of ACTA2 protein CTD PMID:25637568 NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
JBrowse link
G Adipoq adiponectin, C1Q and collagen domain containing multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein] CTD PMID:28285642 NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
JBrowse link
G Agt angiotensinogen multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of AGT mRNA] CTD PMID:28285642 NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
JBrowse link
G Akt1 AKT serine/threonine kinase 1 increases expression ISO boric acid results in increased expression of AKT1 mRNA CTD PMID:31368021 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Arg1 arginase 1 decreases activity ISO boric acid results in decreased activity of ARG1 protein CTD PMID:21232540 NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
JBrowse link
G Atf4 activating transcription factor 4 increases expression ISO boric acid results in increased expression of ATF4 mRNA; boric acid results in increased expression of ATF4 protein CTD PMID:25425213 PMID:27587023 NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
JBrowse link
G Atf6 activating transcription factor 6 multiple interactions ISO boric acid results in increased cleavage of and affects the localization of ATF6 protein CTD PMID:27587023 NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
JBrowse link
G Bax BCL2 associated X, apoptosis regulator decreases expression
multiple interactions
ISO
EXP
boric acid results in decreased expression of BAX mRNA
[boric acid results in increased abundance of Boron] which affects the expression of BAX mRNA; [boric acid results in increased abundance of Boron] which affects the expression of BAX protein
CTD PMID:31368021 PMID:33137424 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bcl2 BCL2, apoptosis regulator increases expression
multiple interactions
ISO
EXP
boric acid results in increased expression of BCL2 mRNA
[boric acid results in increased abundance of Boron] which results in decreased expression of BCL2 mRNA; [boric acid results in increased abundance of Boron] which results in decreased expression of BCL2 protein
CTD PMID:31368021 PMID:33137424 NCBI chr13:22,689,783...22,853,920 JBrowse link
G Calr calreticulin increases expression ISO boric acid results in increased expression of CALR mRNA CTD PMID:27587023 NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
JBrowse link
G Casp3 caspase 3 decreases expression
multiple interactions
ISO boric acid results in decreased expression of CASP3 mRNA
boric acid inhibits the reaction [Formaldehyde results in increased expression of CASP3 mRNA]
CTD PMID:31368021 PMID:31823256 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Cat catalase multiple interactions
decreases activity
EXP
ISO
[boric acid co-treated with Arsenic Trioxide] affects the activity of CAT protein; [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in decreased activity of CAT protein]; boric acid inhibits the reaction [Acrylamide results in increased activity of CAT protein]
boric acid results in decreased activity of CAT protein
boric acid affects the reaction [Formaldehyde results in decreased activity of CAT protein]
CTD PMID:26184899 PMID:29913234 PMID:30997025 PMID:31823256 NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
JBrowse link
G Ccnd1 cyclin D1 multiple interactions
increases expression
ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CCND1 protein]
boric acid results in increased expression of CCND1 mRNA
CTD PMID:28285642 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]] CTD PMID:28285642 NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
JBrowse link
G Cebpb CCAAT/enhancer binding protein beta multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPB mRNA] CTD PMID:28285642 NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
JBrowse link
G Col1a2 collagen type I alpha 2 chain affects expression ISO boric acid affects the expression of COL1A2 mRNA CTD PMID:24704097 NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
JBrowse link
G Csf2 colony stimulating factor 2 increases expression ISO boric acid results in increased expression of CSF2 protein CTD PMID:27206737 NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
JBrowse link
G Csf3 colony stimulating factor 3 increases expression ISO boric acid results in increased expression of CSF3 protein CTD PMID:27206737 NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603
JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CTNNB1 protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]] CTD PMID:28285642 NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 decreases expression ISO boric acid results in decreased expression of DDIT3 mRNA; boric acid results in decreased expression of DDIT3 protein CTD PMID:27587023 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
JBrowse link
G Des desmin affects expression ISO boric acid affects the expression of DES mRNA CTD PMID:25637568 NCBI chr 9:76,850,979...76,858,695
Ensembl chr 9:76,850,982...76,858,699
JBrowse link
G Dvl2 dishevelled segment polarity protein 2 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of DVL2 mRNA] CTD PMID:28285642 NCBI chr10:54,723,356...54,732,823
Ensembl chr10:54,723,411...54,732,820
JBrowse link
G Edem1 ER degradation enhancing alpha-mannosidase like protein 1 increases expression ISO boric acid results in increased expression of EDEM1 mRNA CTD PMID:27587023 NCBI chr 4:141,797,631...141,829,717
Ensembl chr 4:141,797,701...141,829,717
JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 multiple interactions ISO EIF2AK3 protein affects the reaction [boric acid affects the localization of NFE2L2 protein]; EIF2AK3 protein affects the reaction [boric acid results in increased expression of GCLC mRNA]; EIF2AK3 protein affects the reaction [boric acid results in increased phosphorylation of EIF2S1 protein] CTD PMID:30196486 NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha increases phosphorylation
multiple interactions
ISO boric acid results in increased phosphorylation of EIF2S1 protein
EIF2AK3 protein affects the reaction [boric acid results in increased phosphorylation of EIF2S1 protein]
CTD PMID:25425213 PMID:27587023 PMID:30196486 NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
JBrowse link
G Fabp4 fatty acid binding protein 4 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]] CTD PMID:28285642 NCBI chr 2:91,580,858...91,585,578
Ensembl chr 2:91,580,885...91,585,578
JBrowse link
G Fasn fatty acid synthase multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FASN mRNA] CTD PMID:28285642 NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
JBrowse link
G Fgf2 fibroblast growth factor 2 multiple interactions ISO boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FGF2 protein] CTD PMID:28285642 NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
JBrowse link
G Fgf7 fibroblast growth factor 7 increases expression ISO boric acid results in increased expression of FGF7 protein CTD PMID:27206737 NCBI chr 3:113,280,448...113,333,279
Ensembl chr 3:113,281,283...113,332,929
JBrowse link
G Fn1 fibronectin 1 increases expression
affects expression
ISO boric acid results in increased expression of FN1 mRNA
boric acid affects the expression of FN1 mRNA
CTD PMID:27206737 NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
JBrowse link
G Gapdh glyceraldehyde-3-phosphate dehydrogenase decreases expression ISO boric acid results in decreased expression of GAPDH protein CTD PMID:28285642 NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235
JBrowse link
G Gas6 growth arrest specific 6 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of GAS6 protein] CTD PMID:28285642 NCBI chr16:76,045,430...76,075,904
Ensembl chr16:76,045,426...76,075,904
JBrowse link
G Gck glucokinase increases expression ISO boric acid results in increased expression of GCK mRNA CTD PMID:31368021 NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions
increases expression
ISO EIF2AK3 protein affects the reaction [boric acid results in increased expression of GCLC mRNA] CTD PMID:30196486 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions EXP [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of GPT protein] CTD PMID:30997025 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
JBrowse link
G Herpud1 homocysteine inducible ER protein with ubiquitin like domain 1 increases expression ISO boric acid results in increased expression of HERPUD1 mRNA CTD PMID:27587023 NCBI chr19:10,598,411...10,609,002
Ensembl chr19:10,598,417...10,618,424
JBrowse link
G Hmox1 heme oxygenase 1 increases expression ISO boric acid results in increased expression of HMOX1 mRNA CTD PMID:30196486 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
JBrowse link
G Hoxa6 homeobox A6 affects expression EXP boric acid affects the expression of HOXA6 mRNA CTD PMID:12749385 NCBI chr 4:81,304,918...81,313,184
Ensembl chr 4:81,306,407...81,308,850
JBrowse link
G Hoxc6 homeo box C6 affects expression EXP boric acid affects the expression of HOXC6 mRNA CTD PMID:12749385 NCBI chr 7:134,138,017...134,148,899 JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 increases expression ISO boric acid results in increased expression of HSPA5 mRNA; boric acid results in increased expression of HSPA5 protein CTD PMID:25425213 PMID:27587023 NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
JBrowse link
G Ifng interferon gamma multiple interactions EXP [boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased secretion of IFNG protein]; [boric acid results in increased abundance of Boron] which affects the secretion of IFNG protein; boric acid inhibits the reaction [Acrylamide results in increased expression of IFNG mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IFNG mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IFNG protein] CTD PMID:29913234 PMID:30368975 PMID:33137424 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
JBrowse link
G Il10 interleukin 10 multiple interactions EXP [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in decreased expression of IL10 mRNA] CTD PMID:30997025 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
JBrowse link
G Il1b interleukin 1 beta multiple interactions EXP [boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of IL1B mRNA]; boric acid inhibits the reaction [Acrylamide results in increased expression of IL1B mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IL1B mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of IL1B protein] CTD PMID:29913234 PMID:30368975 PMID:30997025 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
JBrowse link
G Il2 interleukin 2 multiple interactions EXP [boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased secretion of IL2 protein]; [boric acid results in increased abundance of Boron] which results in decreased secretion of IL2 protein CTD PMID:33137424 NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
JBrowse link
G Il4 interleukin 4 increases expression
multiple interactions
ISO
EXP
boric acid results in increased expression of IL4 mRNA
[boric acid results in increased abundance of Boron] which affects the secretion of IL4 protein
CTD PMID:31368021 PMID:33137424 NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
JBrowse link
G Il6 interleukin 6 multiple interactions ISO
EXP
boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of IL6 mRNA]
[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of IL6 mRNA]
CTD PMID:28285642 PMID:30997025 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Ins2 insulin 2 multiple interactions
increases expression
ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CCND1 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of CTNNB1 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in decreased expression of DVL2 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of ADIPOQ mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of AGT mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of and results in increased secretion of ADIPOQ protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPB mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FASN mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of GAS6 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of KLF5 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LEP mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LIPE mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SREBF1 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of TNFRSF1A protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK1 protein]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK3 protein]; boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FGF2 protein]; boric acid promotes the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of IL6 mRNA]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of CEBPA protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of FABP4 protein]]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]]
boric acid results in increased expression of INS2 mRNA
CTD PMID:28285642 PMID:31368021 NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
JBrowse link
G Klf5 Kruppel-like factor 5 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of KLF5 mRNA] CTD PMID:28285642 NCBI chr15:76,060,320...76,079,445
Ensembl chr15:76,064,258...76,079,445
JBrowse link
G Lama5 laminin subunit alpha 5 increases expression ISO boric acid results in increased expression of LAMA5 mRNA CTD PMID:27206737 NCBI chr 3:167,270,296...167,318,370
Ensembl chr 3:167,270,296...167,318,451
JBrowse link
G Lep leptin multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LEP mRNA]; boric acid results in decreased expression of and results in decreased secretion of LEP protein CTD PMID:28285642 NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
JBrowse link
G Lipe lipase E, hormone sensitive type multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of LIPE mRNA] CTD PMID:28285642 NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK1 protein] CTD PMID:28285642 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased phosphorylation of MAPK3 protein] CTD PMID:28285642 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Mmp2 matrix metallopeptidase 2 decreases expression ISO boric acid results in decreased expression of MMP2 protein CTD PMID:28285642 NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
JBrowse link
G Myh1 myosin heavy chain 1 affects expression ISO boric acid affects the expression of MYH1 mRNA CTD PMID:25637568 NCBI chr10:51,885,913...51,909,699 JBrowse link
G Myod1 myogenic differentiation 1 affects expression
decreases expression
ISO boric acid affects the expression of MYOD1 mRNA
boric acid results in decreased expression of MYOD1 protein
CTD PMID:25637568 NCBI chr 1:96,884,864...96,887,574
Ensembl chr 1:96,884,948...96,887,554
JBrowse link
G Myog myogenin affects expression ISO boric acid affects the expression of MYOG mRNA CTD PMID:25637568 NCBI chr13:45,745,455...45,748,044
Ensembl chr13:45,745,436...45,748,039
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 affects localization
multiple interactions
ISO boric acid affects the localization of NFE2L2 protein
EIF2AK3 protein affects the reaction [boric acid affects the localization of NFE2L2 protein]
CTD PMID:30196486 NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions
affects expression
ISO boric acid affects the reaction [Formaldehyde results in increased expression of NFKB1 mRNA]
boric acid affects the expression of NFKB1 mRNA
CTD PMID:31823256 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
JBrowse link
G Nos2 nitric oxide synthase 2 multiple interactions ISO boric acid inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA] CTD PMID:27206737 NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases expression ISO boric acid results in increased expression of NQO1 mRNA CTD PMID:30196486 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
JBrowse link
G Pcna proliferating cell nuclear antigen increases expression
multiple interactions
EXP boric acid results in increased expression of PCNA protein
[boric acid results in increased abundance of Boron] promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline results in decreased expression of PCNA protein]; [boric acid results in increased abundance of Boron] which affects the expression of PCNA protein; [boric acid results in increased abundance of Boron] which results in decreased expression of PCNA mRNA
CTD PMID:17943231 PMID:33137424 NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
JBrowse link
G Pdx1 pancreatic and duodenal homeobox 1 increases expression ISO boric acid results in increased expression of PDX1 mRNA CTD PMID:31368021 NCBI chr12:7,757,865...7,763,064
Ensembl chr12:7,757,865...7,763,064
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]; CTNNB1 protein promotes the reaction [boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of PPARG protein]] CTD PMID:28285642 NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
JBrowse link
G Ppp1r15a protein phosphatase 1, regulatory subunit 15A increases expression ISO boric acid results in increased expression of PPP1R15A mRNA; boric acid results in increased expression of PPP1R15A protein CTD PMID:27587023 NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:96,000,058...96,003,171
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO boric acid inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA] CTD PMID:27206737 NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions EXP boric acid inhibits the reaction [Acrylamide results in increased expression of RELA mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of RELA mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of RELA protein] CTD PMID:29913234 PMID:30368975 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
JBrowse link
G Runx2 RUNX family transcription factor 2 affects expression ISO boric acid affects the expression of RUNX2 mRNA CTD PMID:24704097 NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
JBrowse link
G Slc2a2 solute carrier family 2 member 2 increases expression ISO boric acid results in increased expression of SLC2A2 mRNA CTD PMID:31368021 NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933
JBrowse link
G Slc2a4 solute carrier family 2 member 4 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 mRNA]; boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SLC2A4 protein] CTD PMID:28285642 NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
JBrowse link
G Slc4a2 solute carrier family 4 member 2 increases expression ISO boric acid results in increased expression of SLC4A2 mRNA CTD PMID:22576912 NCBI chr 4:10,736,419...10,754,407
Ensembl chr 4:10,736,425...10,752,965
JBrowse link
G Slc4a3 solute carrier family 4 member 3 increases expression ISO boric acid results in increased expression of SLC4A3 mRNA CTD PMID:22576912 NCBI chr 9:77,036,243...77,053,940
Ensembl chr 9:77,037,016...77,049,105
JBrowse link
G Sparc secreted protein acidic and cysteine rich affects expression ISO boric acid affects the expression of SPARC mRNA CTD PMID:24704097 NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of SREBF1 mRNA] CTD PMID:28285642 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
JBrowse link
G Syvn1 synoviolin 1 decreases expression ISO boric acid results in decreased expression of SYVN1 mRNA CTD PMID:27587023 NCBI chr 1:203,339,235...203,346,137
Ensembl chr 1:203,339,619...203,346,152
JBrowse link
G Tgfb1 transforming growth factor, beta 1 increases expression ISO boric acid results in increased expression of TGFB1 protein
boric acid results in increased expression of TGFB1 mRNA
CTD PMID:27206737 PMID:31368021 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
JBrowse link
G Tnf tumor necrosis factor multiple interactions
decreases expression
increases secretion
increases expression
ISO
EXP
boric acid inhibits the reaction [Formaldehyde results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
boric acid results in decreased expression of TNF mRNA
[boric acid results in increased abundance of Boron] inhibits the reaction [bisphenol A results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Acrylamide results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of TNF mRNA]; boric acid inhibits the reaction [Arsenic Trioxide results in increased expression of TNF protein]
boric acid results in increased secretion of TNF protein
boric acid results in increased expression of TNF mRNA
CTD PMID:9618283 PMID:18755394 PMID:29913234 PMID:30368975 PMID:30997025 More... NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
JBrowse link
G Tnfrsf1a TNF receptor superfamily member 1A multiple interactions ISO boric acid inhibits the reaction [[Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with INS protein] results in increased expression of TNFRSF1A protein] CTD PMID:28285642 NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
JBrowse link
G Tp53 tumor protein p53 decreases expression ISO boric acid results in decreased expression of TRP53 mRNA CTD PMID:31368021 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
JBrowse link
G Xbp1 X-box binding protein 1 increases expression ISO boric acid results in increased expression of XBP1 mRNA CTD PMID:27587023 NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
JBrowse link
boric acids term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Ggt1 gamma-glutamyltransferase 1 decreases activity EXP Boric Acids analog results in decreased activity of GGT1 protein CTD PMID:6149445 NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442
JBrowse link
G Muc1 mucin 1, cell surface associated decreases expression ISO Boric Acids results in decreased expression of MUC1 mRNA CTD PMID:21060261 NCBI chr 2:174,635,559...174,640,738
Ensembl chr 2:174,635,995...174,640,733
JBrowse link
G Muc16 mucin 16, cell surface associated decreases expression ISO Boric Acids results in decreased expression of MUC16 mRNA CTD PMID:21060261 NCBI chr 8:16,164,531...16,323,126 JBrowse link
bortezomib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abca2 ATP binding cassette subfamily A member 2 decreases expression ISO Bortezomib results in decreased expression of ABCA2 mRNA CTD PMID:20977926 NCBI chr 3:8,244,515...8,264,545
Ensembl chr 3:8,244,639...8,264,537
JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions
decreases expression
decreases activity
ISO [Bortezomib co-treated with Doxorubicin] results in decreased expression of ABCB1 protein; ATP2A1 protein affects the reaction [Bortezomib results in decreased expression of ABCB1]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1 mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1 protein]; Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1 protein; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1 mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1 protein]
[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein; Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1A mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1A protein]; Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1A protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1A mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1A protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]]
Bortezomib results in decreased expression of ABCB1; Bortezomib results in decreased expression of ABCB1 mRNA; Bortezomib results in decreased expression of ABCB1 protein
Bortezomib results in decreased activity of ABCB1 protein
CTD PMID:25576094 PMID:30482226 PMID:33775688 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
JBrowse link
G Abcc1 ATP binding cassette subfamily C member 1 decreases expression
multiple interactions
ISO Bortezomib results in decreased expression of ABCC1 mRNA
[Bortezomib co-treated with Doxorubicin] results in decreased expression of ABCC1 protein
CTD PMID:20977926 PMID:33775688 NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
JBrowse link
G Abcc2 ATP binding cassette subfamily C member 2 increases expression ISO Bortezomib results in increased expression of ABCC2 mRNA CTD PMID:21215737 NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
JBrowse link
G Abcc4 ATP binding cassette subfamily C member 4 decreases expression ISO Bortezomib results in decreased expression of ABCC4 mRNA CTD PMID:20977926 NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
JBrowse link
G Abhd16a abhydrolase domain containing 16A, phospholipase increases expression ISO Bortezomib results in increased expression of ABHD16A mRNA CTD PMID:20977926 NCBI chr20:3,719,089...3,733,952
Ensembl chr20:3,719,091...3,733,927
JBrowse link
G Abhd2 abhydrolase domain containing 2, acylglycerol lipase increases expression ISO Bortezomib results in increased expression of ABHD2 mRNA CTD PMID:20977926 NCBI chr 1:133,217,403...133,298,564
Ensembl chr 1:133,217,375...133,299,061
JBrowse link
G Abi1 abl-interactor 1 increases expression ISO Bortezomib results in increased expression of ABI1 mRNA CTD PMID:20977926 NCBI chr17:85,098,837...85,179,829
Ensembl chr17:85,098,550...85,179,792
JBrowse link
G Abl1 ABL proto-oncogene 1, non-receptor tyrosine kinase multiple interactions ISO [alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein; [alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein; [alvocidib co-treated with Bortezomib] results in decreased expression of ABL1 protein; [Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of ABL1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in decreased expression of ABL1 protein; Bortezomib promotes the reaction [Dichlororibofuranosylbenzimidazole results in decreased expression of ABL1 protein] CTD PMID:15039284 PMID:17495969 PMID:21195056 NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065
JBrowse link
G Ace angiotensin I converting enzyme multiple interactions ISO [Butyrates co-treated with Bortezomib] results in increased activity of ACE protein mutant form CTD PMID:20454656 NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
JBrowse link
G Acot7 acyl-CoA thioesterase 7 decreases expression ISO Bortezomib results in decreased expression of ACOT7 mRNA CTD PMID:20977926 NCBI chr 5:162,686,562...162,779,309
Ensembl chr 5:162,684,645...162,779,309
JBrowse link
G Adam10 ADAM metallopeptidase domain 10 decreases expression ISO Bortezomib results in decreased expression of ADAM10 mRNA CTD PMID:20977926 NCBI chr 8:71,346,008...71,477,889
Ensembl chr 8:71,345,837...71,477,889
JBrowse link
G Adm adrenomedullin multiple interactions
decreases expression
ISO Bortezomib inhibits the reaction [arsenic trioxide results in decreased expression of ADM mRNA]
Bortezomib results in decreased expression of ADM mRNA
CTD PMID:20471514 NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
JBrowse link
G Aff1 AF4/FMR2 family, member 1 increases expression ISO Bortezomib results in increased expression of AFF1 mRNA CTD PMID:20977926 NCBI chr14:5,861,188...6,024,196
Ensembl chr14:5,863,961...6,024,729
JBrowse link
G Aff4 AF4/FMR2 family, member 4 increases expression ISO Bortezomib results in increased expression of AFF4 mRNA CTD PMID:20977926 NCBI chr10:37,498,825...37,579,751
Ensembl chr10:37,498,825...37,579,751
JBrowse link
G Agk acylglycerol kinase decreases expression ISO Bortezomib results in decreased expression of AGK mRNA CTD PMID:20977926 NCBI chr 4:69,114,850...69,193,989
Ensembl chr 4:69,114,269...69,193,934
JBrowse link
G Agrn agrin decreases expression ISO Bortezomib results in decreased expression of AGRN mRNA CTD PMID:20977926 NCBI chr 5:166,749,306...166,782,212
Ensembl chr 5:166,749,310...166,786,003
JBrowse link
G Agtpbp1 ATP/GTP binding carboxypeptidase 1 increases expression ISO Bortezomib results in increased expression of AGTPBP1 mRNA CTD PMID:20977926 NCBI chr17:5,120,540...5,238,874
Ensembl chr17:5,120,609...5,238,869
JBrowse link
G Agtrap angiotensin II receptor-associated protein decreases expression ISO Bortezomib results in decreased expression of AGTRAP mRNA CTD PMID:20977926 NCBI chr 5:158,507,427...158,519,036
Ensembl chr 5:158,508,749...158,519,036
JBrowse link
G Aifm1 apoptosis inducing factor, mitochondria associated 1 affects localization
multiple interactions
ISO Bortezomib affects the localization of AIFM1 protein
[Bortezomib co-treated with Butyrates] affects the localization of AIFM1 protein; [Bortezomib co-treated with vorinostat] affects the localization of AIFM1 protein
CTD PMID:12893773 PMID:16024631 NCBI chr  X:127,650,223...127,689,356
Ensembl chr  X:127,650,226...127,689,256
JBrowse link
G Aifm2 apoptosis inducing factor, mitochondria associated 2 increases expression ISO Bortezomib results in increased expression of AIFM2 mRNA CTD PMID:20977926 NCBI chr20:29,654,283...29,679,239
Ensembl chr20:29,652,927...29,679,236
JBrowse link
G Aim2 absent in melanoma 2 increases expression ISO Bortezomib results in increased expression of AIM2 mRNA CTD PMID:20977926 NCBI chr13:85,865,206...85,906,996
Ensembl chr13:85,866,284...85,906,975
JBrowse link
G Akr1b1 aldo-keto reductase family 1 member B increases expression ISO Bortezomib results in increased expression of AKR1B1 mRNA; Bortezomib results in increased expression of AKR1B1 protein CTD PMID:21215737 NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
JBrowse link
G Akr1b10 aldo-keto reductase family 1 member B10 increases expression ISO Bortezomib results in increased expression of AKR1B10 mRNA; Bortezomib results in increased expression of AKR1B10 protein CTD PMID:21215737 NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
JBrowse link
G Akr1b8 aldo-keto reductase family 1, member B8 increases expression EXP Bortezomib results in increased expression of AKR1B8 mRNA CTD PMID:20830808 NCBI chr 4:62,997,241...63,009,815 JBrowse link
G Akr1c2 aldo-keto reductase family 1, member C2 affects expression ISO Bortezomib affects the expression of AKR1C2 mRNA CTD PMID:21215737 NCBI chr17:65,759,778...65,808,013
Ensembl chr17:65,759,788...65,775,764
JBrowse link
G Akr1c3 aldo-keto reductase family 1, member C3 increases expression ISO Bortezomib results in increased expression of AKR1C3 mRNA CTD PMID:21215737 NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
JBrowse link
G Akr7a2 aldo-keto reductase family 7, member A2 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of AKR7A2 mRNA CTD PMID:25522274 NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
decreases expression
decreases activity
ISO [alvocidib co-treated with Bortezomib] results in decreased expression of AKT1 protein modified form; [Bortezomib co-treated with lapatinib] results in decreased phosphorylation of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein; [Bortezomib co-treated with lonafarnib] results in decreased expression of AKT1 protein modified form; [Bortezomib co-treated with panobinostat] results in decreased activity of AKT1 protein; [Bortezomib co-treated with sorafenib] results in decreased phosphorylation of AKT1 protein; [Bortezomib results in decreased activity of CBL protein] promotes the reaction [arsenic trioxide results in increased activity of AKT1 protein]; [geldanamycin co-treated with Bortezomib] results in decreased expression of AKT1 protein; [vorinostat co-treated with Bortezomib] results in decreased phosphorylation of and results in decreased expression of AKT1 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP3 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of CASP9 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with sorafenib] results in increased cleavage of PARP1 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein]; AKT1 protein results in decreased susceptibility to [Bortezomib co-treated with sorafenib]; Bortezomib inhibits the reaction [TNFSF10 protein results in increased activity of AKT1 protein]; Okadaic Acid inhibits the reaction [Bortezomib results in decreased expression of AKT1 protein modified form]
Bortezomib results in decreased activity of AKT1 protein
CTD PMID:15039284 PMID:15781649 PMID:16118318 PMID:16985072 PMID:18445700 More... NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
JBrowse link
G Aldh18a1 aldehyde dehydrogenase 18 family, member A1 decreases expression ISO Bortezomib results in decreased expression of ALDH18A1 mRNA CTD PMID:20977926 NCBI chr 1:239,375,657...239,407,967
Ensembl chr 1:239,375,669...239,407,890
JBrowse link
G Aldh5a1 aldehyde dehydrogenase 5 family, member A1 decreases expression ISO Bortezomib results in decreased expression of ALDH5A1 mRNA CTD PMID:20977926 NCBI chr17:40,132,339...40,158,677
Ensembl chr17:40,130,883...40,158,677
JBrowse link
G Aldh6a1 aldehyde dehydrogenase 6 family, member A1 decreases expression ISO Bortezomib results in decreased expression of ALDH6A1 mRNA CTD PMID:20977926 NCBI chr 6:104,077,975...104,098,636
Ensembl chr 6:104,077,979...104,098,656
JBrowse link
G Alox12 arachidonate 12-lipoxygenase, 12S type increases response to substance ISO ALOX12 gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr10:54,958,263...54,970,542
Ensembl chr10:54,958,271...54,970,542
JBrowse link
G Anapc11 anaphase promoting complex subunit 11 decreases expression ISO Bortezomib results in decreased expression of ANAPC11 mRNA CTD PMID:17659339 NCBI chr10:105,875,209...105,886,307 JBrowse link
G Anapc5 anaphase-promoting complex subunit 5 decreases expression
increases expression
ISO Bortezomib results in decreased expression of ANAPC5 mRNA
Bortezomib results in increased expression of ANAPC5 mRNA
CTD PMID:17895889 PMID:20977926 NCBI chr12:33,748,714...33,781,709
Ensembl chr12:33,748,735...33,781,781
JBrowse link
G Ankrd9 ankyrin repeat domain 9 increases expression ISO Bortezomib results in increased expression of ANKRD9 mRNA CTD PMID:20977926 NCBI chr 6:130,001,914...130,008,792
Ensembl chr 6:129,998,486...130,008,923
JBrowse link
G Ano10 anoctamin 10 increases expression ISO Bortezomib results in increased expression of ANO10 mRNA CTD PMID:20977926 NCBI chr 8:121,841,664...121,960,739
Ensembl chr 8:121,841,665...121,962,670
JBrowse link
G Ap1s1 adaptor related protein complex 1 subunit sigma 1 decreases expression ISO Bortezomib results in decreased expression of AP1S1 mRNA CTD PMID:20977926 NCBI chr12:19,625,267...19,635,792
Ensembl chr12:19,625,332...19,756,713
JBrowse link
G Ap2a1 adaptor related protein complex 2 subunit alpha 1 decreases expression ISO Bortezomib results in decreased expression of AP2A1 mRNA CTD PMID:20977926 NCBI chr 1:95,384,303...95,414,249
Ensembl chr 1:95,384,309...95,414,147
JBrowse link
G Apobr apolipoprotein B receptor decreases expression ISO Bortezomib results in decreased expression of APOBR mRNA CTD PMID:20977926 NCBI chr 1:181,168,982...181,173,528
Ensembl chr 1:181,168,916...181,173,528
JBrowse link
G Apool apolipoprotein O-like increases expression ISO Bortezomib results in increased expression of APOOL mRNA CTD PMID:20977926 NCBI chr  X:77,377,685...77,443,670
Ensembl chr  X:77,377,781...77,443,900
JBrowse link
G Aqp3 aquaporin 3 (Gill blood group) increases expression ISO Bortezomib results in increased expression of AQP3 mRNA CTD PMID:20977926 NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
JBrowse link
G Ar androgen receptor multiple interactions ISO Bortezomib binds to and results in decreased activity of AR protein; Bortezomib inhibits the reaction [Metribolone results in increased activity of AR protein] CTD PMID:25752796 PMID:30818834 NCBI chr  X:63,104,771...63,273,934
Ensembl chr  X:63,104,771...63,273,925
JBrowse link
G Arf6 ADP-ribosylation factor 6 increases expression ISO Bortezomib results in increased expression of ARF6 mRNA CTD PMID:20977926 NCBI chr 6:87,853,742...87,854,890
Ensembl chr 6:87,840,142...87,874,114
JBrowse link
G Arfgap1 ADP-ribosylation factor GTPase activating protein 1 decreases expression ISO Bortezomib results in decreased expression of ARFGAP1 mRNA CTD PMID:20977926 NCBI chr 3:168,084,560...168,099,948
Ensembl chr 3:168,084,614...168,099,933
JBrowse link
G Arhgap1 Rho GTPase activating protein 1 decreases expression ISO Bortezomib results in decreased expression of ARHGAP1 mRNA CTD PMID:20977926 NCBI chr 3:77,621,377...77,643,400
Ensembl chr 3:77,620,655...77,643,396
JBrowse link
G Arhgdia Rho GDP dissociation inhibitor alpha decreases expression ISO Bortezomib results in decreased expression of ARHGDIA mRNA CTD PMID:20977926 NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023
JBrowse link
G Arid3b AT-rich interaction domain 3B multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ARID3B mRNA CTD PMID:25522274 NCBI chr 8:58,193,268...58,240,901
Ensembl chr 8:58,193,418...58,238,318
JBrowse link
G Arl4c ADP ribosylation factor like GTPase 4C decreases expression ISO Bortezomib results in decreased expression of ARL4C mRNA CTD PMID:20977926 NCBI chr 9:89,300,335...89,303,770
Ensembl chr 9:89,298,005...89,304,513
JBrowse link
G Arl8a ADP-ribosylation factor like GTPase 8A increases expression ISO Bortezomib results in increased expression of ARL8A mRNA CTD PMID:20977926 NCBI chr13:46,585,845...46,594,851
Ensembl chr13:46,585,845...46,594,851
JBrowse link
G Arrb1 arrestin, beta 1 decreases expression ISO Bortezomib results in decreased expression of ARRB1 mRNA CTD PMID:20977926 NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061
JBrowse link
G Asap1 ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 decreases expression ISO Bortezomib results in decreased expression of ASAP1 mRNA CTD PMID:20977926 NCBI chr 7:95,786,130...96,093,111
Ensembl chr 7:95,787,818...96,092,754
JBrowse link
G Ate1 arginyltransferase 1 increases expression ISO Bortezomib results in increased expression of ATE1 mRNA CTD PMID:20977926 NCBI chr 1:184,961,548...185,081,112
Ensembl chr 1:184,963,562...185,080,908
JBrowse link
G Atf2 activating transcription factor 2 multiple interactions
increases phosphorylation
increases expression
ISO pyrazolanthrone inhibits the reaction [Bortezomib results in increased phosphorylation of ATF2 protein]
Bortezomib results in increased expression of ATF2 mRNA
CTD PMID:12393500 PMID:20977926 NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236
JBrowse link
G Atf3 activating transcription factor 3 increases response to substance
increases expression
multiple interactions
ISO
EXP
ATF3 results in increased susceptibility to Bortezomib
Bortezomib results in increased expression of ATF3 mRNA; Bortezomib results in increased expression of ATF3 protein
Bortezomib results in increased expression of ATF3; Bortezomib results in increased expression of ATF3 mRNA; Bortezomib results in increased expression of ATF3 protein
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ATF3 mRNA; ATF3 mutant form promotes the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]
CTD PMID:17898295 PMID:20022965 PMID:20830808 PMID:21762082 PMID:25522274 NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
JBrowse link
G Atf4 activating transcription factor 4 multiple interactions
increases expression
decreases response to substance
ISO 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased expression of ATF4 protein]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 mRNA]; ATF4 mutant form inhibits the reaction [Bortezomib results in increased expression of PMAIP1 protein]; Bortezomib promotes the reaction [ATF4 protein binds to PMAIP1 promoter]; Dactinomycin inhibits the reaction [Bortezomib results in increased expression of ATF4 mRNA]; Dactinomycin inhibits the reaction [Bortezomib results in increased expression of ATF4 protein]; NUPR1 mutant form promotes the reaction [Bortezomib results in increased expression of ATF4 mRNA]
Bortezomib results in increased expression of ATF4 mRNA; Bortezomib results in increased expression of ATF4 protein
ATF4 results in decreased susceptibility to Bortezomib
CTD PMID:15509775 PMID:16928686 PMID:20022965 NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
JBrowse link
G Atf5 activating transcription factor 5 increases expression ISO Bortezomib results in increased expression of ATF5 mRNA CTD PMID:17898295 NCBI chr 1:95,295,602...95,299,755
Ensembl chr 1:95,295,610...95,299,707
JBrowse link
G Atg5 autophagy related 5 multiple interactions ISO ATG5 gene mutant form inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]] CTD PMID:22842577 NCBI chr20:47,798,222...47,889,216
Ensembl chr20:47,798,290...47,889,209
JBrowse link
G Atm ATM serine/threonine kinase multiple interactions
increases cleavage
ISO [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of ATM protein] CTD PMID:12393500 NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
JBrowse link
G Atp1a3 ATPase Na+/K+ transporting subunit alpha 3 decreases expression ISO Bortezomib results in decreased expression of ATP1A3 mRNA CTD PMID:20977926 NCBI chr 1:80,572,790...80,601,936
Ensembl chr 1:80,572,796...80,601,918
JBrowse link
G Atp2a1 ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 1 multiple interactions
affects response to substance
ISO ATP2A1 protein affects the reaction [Bortezomib results in decreased expression of ABCB1]
ATP2A1 protein affects the susceptibility to Bortezomib
CTD PMID:25576094 NCBI chr 1:181,026,606...181,044,859 JBrowse link
G Atp6v0e1 ATPase H+ transporting V0 subunit e1 increases expression ISO Bortezomib results in increased expression of ATP6V0E1 mRNA CTD PMID:20977926 NCBI chr10:16,479,656...16,502,732
Ensembl chr10:16,479,567...16,524,434
JBrowse link
G B2m beta-2 microglobulin decreases expression ISO Bortezomib results in decreased expression of B2M protein CTD PMID:17204182 NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766
JBrowse link
G B3gnt2 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 decreases expression ISO Bortezomib results in decreased expression of B3GNT2 mRNA CTD PMID:20977926 NCBI chr14:96,808,473...96,833,674
Ensembl chr14:96,806,664...96,835,273
JBrowse link
G B4galt6 beta-1,4-galactosyltransferase 6 increases expression ISO Bortezomib results in increased expression of B4GALT6 mRNA CTD PMID:20977926 NCBI chr18:11,958,382...12,015,247
Ensembl chr18:11,958,390...12,015,247
JBrowse link
G Bag3 BAG cochaperone 3 increases expression ISO Bortezomib results in increased expression of BAG3 mRNA CTD PMID:15509775 PMID:17659339 PMID:20471514 NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858
JBrowse link
G Bak1 BCL2-antagonist/killer 1 multiple interactions
increases expression
ISO [nutlin 3 co-treated with Bortezomib] results in increased activity of BAK1 protein; BAK1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]
BAK1 protein results in increased susceptibility to [Bortezomib co-treated with TNFSF10 protein]
Bortezomib results in increased expression of BAK1 protein
CTD PMID:12902978 PMID:17326159 PMID:20850924 NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
JBrowse link
G Bard1 BRCA1 associated RING domain 1 increases response to substance ISO BARD1 mutant form results in increased susceptibility to Bortezomib CTD PMID:25522274 NCBI chr 9:72,616,070...72,694,553
Ensembl chr 9:72,623,155...72,694,265
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions
increases expression
ISO [Bortezomib co-treated with arsenic trioxide] affects the expression of BAX protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of BAX protein; BAX results in increased susceptibility to [Bortezomib co-treated with panobinostat]; Bortezomib inhibits the reaction [BAX mutant form inhibits the reaction [TNFSF10 protein results in increased localization of DIABLO protein]]
Bortezomib results in increased expression of BAX protein
CTD PMID:12902978 PMID:18445700 PMID:18718063 PMID:20383943 PMID:20850924 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
JBrowse link
G Bbc3 Bcl-2 binding component 3 increases expression ISO Bortezomib results in increased expression of BBC3 mRNA; Bortezomib results in increased expression of BBC3 protein CTD PMID:17898295 PMID:20051518 NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
JBrowse link
G Bbln bublin coiled coil protein decreases expression ISO Bortezomib results in decreased expression of BBLN mRNA CTD PMID:20977926 NCBI chr 3:15,674,577...15,677,393
Ensembl chr 3:15,674,580...15,677,374
JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions
increases expression
increases cleavage
decreases expression
ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with arsenic trioxide] affects the expression of BCL2 protein; [Bortezomib co-treated with arsenic trioxide] results in decreased expression of BCL2 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of BCL2 protein; [Bortezomib co-treated with Daunorubicin] results in decreased expression of BCL2 mRNA; [Bortezomib co-treated with vorinostat] results in increased cleavage of BCL2 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2 protein; [vorinostat co-treated with Bortezomib] results in decreased expression of BCL2 protein; BCL2 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2 protein modified form]
Bortezomib results in increased expression of BCL2 mRNA; Bortezomib results in increased expression of BCL2 protein
Bortezomib results in decreased expression of BCL2 mRNA; Bortezomib results in decreased expression of BCL2 protein
CTD PMID:15173093 PMID:15781649 PMID:16022909 PMID:16118318 PMID:16446371 More... NCBI chr13:22,689,783...22,853,920 JBrowse link
G Bcl2a1 BCL2-related protein A1 multiple interactions
increases expression
ISO [romidepsin co-treated with Bortezomib] results in decreased expression of BCL2A1 protein
Bortezomib results in increased expression of BCL2A1A protein
CTD PMID:18223231 PMID:20051518 NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998
JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions
decreases expression
increases expression
increases cleavage
decreases response to substance
ISO [alvocidib co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [romidepsin co-treated with Bortezomib] results in decreased expression of BCL2L1 protein; [vorinostat co-treated with Bortezomib] results in decreased expression of BCL2L1 protein alternative form; [vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 mRNA alternative form; [vorinostat co-treated with Bortezomib] results in increased expression of BCL2L1 protein alternative form; BCL2L1 affects the reaction [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein]; BCL2L1 protein results in decreased susceptibility to [Bortezomib co-treated with trichostatin A]; lonafarnib promotes the reaction [Bortezomib results in increased cleavage of BCL2L1 protein]; SCIO-469 promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 mRNA]; trichostatin A promotes the reaction [Bortezomib results in decreased expression of BCL2L1 protein]
Bortezomib results in decreased expression of BCL2L1 mRNA; Bortezomib results in decreased expression of BCL2L1 protein
Bortezomib results in increased expression of BCL2L1 protein
BCL2L1 protein results in decreased susceptibility to Bortezomib
CTD PMID:15039284 PMID:15543232 PMID:15781649 PMID:16118318 PMID:16446371 More... NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
JBrowse link
G Bcl2l11 BCL2 like 11 multiple interactions
increases expression
increases activity
increases response to substance
ISO [Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased expression of BCL2L11 protein]
Bortezomib results in increased expression of BCL2L11 protein
Bortezomib results in increased activity of BCL2L11 protein
BCL2L11 results in increased susceptibility to Bortezomib
CTD PMID:15173094 PMID:16024631 PMID:16446371 PMID:17326159 PMID:18566236 NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
JBrowse link
G Bcl2l2 Bcl2-like 2 increases expression ISO Bortezomib results in increased expression of BCL2L2 mRNA CTD PMID:18928586 NCBI chr15:28,346,449...28,361,627
Ensembl chr15:28,356,807...28,361,624
JBrowse link
G Bcl3 BCL3, transcription coactivator multiple interactions
decreases expression
ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of BCL3 mRNA
Bortezomib results in decreased expression of BCL3 mRNA
CTD PMID:20471514 PMID:20977926 NCBI chr 1:79,471,368...79,485,908
Ensembl chr 1:79,471,369...79,485,607
JBrowse link
G Bcl6 BCL6, transcription repressor increases expression ISO Bortezomib results in increased expression of BCL6 mRNA CTD PMID:20977926 NCBI chr11:76,854,090...76,877,389
Ensembl chr11:76,854,090...76,877,389
JBrowse link
G Bcl7a BAF chromatin remodeling complex subunit BCL7A decreases expression ISO Bortezomib results in decreased expression of BCL7A mRNA CTD PMID:20977926 NCBI chr12:33,211,978...33,243,886
Ensembl chr12:33,223,931...33,243,886
JBrowse link
G Bcr BCR activator of RhoGEF and GTPase decreases expression ISO Bortezomib results in decreased expression of BCR mRNA CTD PMID:20977926 NCBI chr20:13,471,679...13,596,497
Ensembl chr20:13,471,668...13,597,016
JBrowse link
G Becn1 beclin 1 multiple interactions
decreases response to substance
ISO BECN1 mutant form promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]
BECN1 protein results in decreased susceptibility to Bortezomib
CTD PMID:22842577 NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
JBrowse link
G Bid BH3 interacting domain death agonist increases cleavage
multiple interactions
ISO Bortezomib results in increased cleavage of BID protein
[Bortezomib co-treated with Butyrates] results in decreased expression of BID protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of BID protein; [Bortezomib co-treated with vorinostat] results in decreased expression of BID protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of BID protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of BID protein; [vorinostat co-treated with Bortezomib] results in increased cleavage of BID protein; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of BID protein]
CTD PMID:12893773 PMID:12902978 PMID:15930312 PMID:17326159 PMID:17351739 More... NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
JBrowse link
G Bik BCL2-interacting killer increases response to substance
increases expression
increases activity
ISO BIK results in increased susceptibility to Bortezomib
Bortezomib results in increased expression of BIK protein
Bortezomib results in increased activity of BIK protein
CTD PMID:16446371 PMID:18566236 NCBI chr 7:114,672,277...114,691,296
Ensembl chr 7:114,672,277...114,691,296
JBrowse link
G Bin1 bridging integrator 1 increases expression ISO Bortezomib results in increased expression of BIN1 mRNA CTD PMID:17659339 NCBI chr18:24,009,731...24,067,267
Ensembl chr18:24,009,653...24,067,263
JBrowse link
G Birc2 baculoviral IAP repeat-containing 2 decreases expression
multiple interactions
ISO Bortezomib results in decreased expression of BIRC2 protein
[geldanamycin co-treated with Bortezomib] results in decreased expression of BIRC2 protein; [romidepsin co-treated with Bortezomib] results in decreased expression of BIRC2 protein
CTD PMID:15543232 PMID:15781649 PMID:17626072 PMID:18223231 NCBI chr 8:4,968,856...4,989,325
Ensembl chr 8:4,968,842...4,988,732
JBrowse link
G Birc3 baculoviral IAP repeat-containing 3 decreases expression
increases expression
multiple interactions
ISO Bortezomib results in decreased expression of BIRC3 protein
Bortezomib results in increased expression of BIRC3 mRNA; Bortezomib results in increased expression of BIRC3 protein
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of BIRC3 mRNA
CTD PMID:17626072 PMID:24085292 PMID:25522274 NCBI chr 8:5,000,844...5,028,470
Ensembl chr 8:5,000,845...5,015,802
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 decreases expression
multiple interactions
increases expression
ISO Bortezomib results in decreased expression of BIRC5 mRNA; Bortezomib results in decreased expression of BIRC5 protein
[irinotecan co-treated with Bortezomib] results in decreased expression of BIRC5 protein; [romidepsin co-treated with Bortezomib] results in increased cleavage of BIRC5 protein
Bortezomib results in increased expression of BIRC5 protein
CTD PMID:16373703 PMID:17510429 PMID:17898295 PMID:18223231 PMID:18850583 More... NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
JBrowse link
G Birc7 baculoviral IAP repeat-containing 7 multiple interactions
decreases expression
ISO arsenic trioxide promotes the reaction [Bortezomib results in decreased expression of BIRC7 mRNA] CTD PMID:21867610 NCBI chr 3:168,047,824...168,052,606
Ensembl chr 3:168,047,824...168,052,606
JBrowse link
G Bles03 basophilic leukemia expressed protein BLES03 decreases expression ISO Bortezomib results in decreased expression of C11ORF68 mRNA CTD PMID:20977926 NCBI chr 1:202,734,555...202,736,809
Ensembl chr 1:202,734,555...202,736,804
JBrowse link
G Blk BLK proto-oncogene, Src family tyrosine kinase decreases expression ISO Bortezomib results in decreased expression of BLK mRNA CTD PMID:20977926 NCBI chr15:37,626,746...37,665,053
Ensembl chr15:37,627,039...37,665,031
JBrowse link
G Blvrb biliverdin reductase B increases expression ISO Bortezomib results in increased expression of BLVRB mRNA CTD PMID:20977926 NCBI chr 1:82,738,646...82,756,312
Ensembl chr 1:82,738,695...82,770,375
JBrowse link
G Bnip3 BCL2 interacting protein 3 increases expression ISO Bortezomib results in increased expression of BNIP3 protein CTD PMID:20110775 NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
JBrowse link
G Brca1 BRCA1, DNA repair associated decreases expression
multiple interactions
increases response to substance
decreases ubiquitination
ISO Bortezomib results in decreased expression of BRCA1 mRNA
BRCA1 protein inhibits the reaction [BRCA1 gene mutant form results in increased susceptibility to Bortezomib]
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of AKR7A2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNF mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNG2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CRYGEP mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DAPK2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DLGAP5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of EGLN3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of FZD2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of H3C6 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of LGR4 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of RPS7P5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of THRA mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNFAIP8L1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of TNKS mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased activity of E2F1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ARID3B mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ATF3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of BIRC3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CCNB1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CRYAB mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CTH mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of DUSP5 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ERN1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of FGF21 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GADD45A mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GDF15 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HECW1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HIKESHI mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of IL7R mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of KRTAP21-1 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of MIR568 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PAWR mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of PCYT1A mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of RND3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFAIP3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TNFRSF9 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIB3 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of TRIML2 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ZNF613 mRNA; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein]; TP53BP1 protein affects the reaction [[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased phosphorylation of RB1 protein]
Bortezomib results in decreased ubiquitination of BRCA1 protein
CTD PMID:21917757 PMID:25522274 NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304
JBrowse link
G Brca2 BRCA2, DNA repair associated decreases expression
multiple interactions
ISO Bortezomib results in decreased expression of BRCA2 mRNA
[arsenic trioxide co-treated with Bortezomib] results in increased expression of BRCA2 mRNA
CTD PMID:21917757 PMID:25913414 NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567
JBrowse link
G Brcc3 BRCA1/BRCA2-containing complex, subunit 3 decreases expression ISO Bortezomib results in decreased expression of BRCC3 mRNA CTD PMID:20977926 NCBI chr 9:1,986,942...1,989,484
Ensembl chr 9:1,986,575...1,991,080
JBrowse link
G Brf2 BRF2, RNA polymerase III transcription initiation factor subunit increases expression ISO Bortezomib results in increased expression of BRF2 mRNA CTD PMID:20977926 NCBI chr16:64,928,334...64,933,057
Ensembl chr16:64,928,300...64,933,059
JBrowse link
G Bsdc1 BSD domain containing 1 increases expression ISO Bortezomib results in increased expression of BSDC1 mRNA CTD PMID:20977926 NCBI chr 5:141,798,918...141,827,091
Ensembl chr 5:141,798,981...141,827,092
JBrowse link
G Ca9 carbonic anhydrase 9 decreases expression ISO Bortezomib results in decreased expression of CA9 protein CTD PMID:16061869 NCBI chr 5:57,763,234...57,769,838
Ensembl chr 5:57,763,206...57,769,838
JBrowse link
G Caap1 caspase activity and apoptosis inhibitor 1 increases expression ISO Bortezomib results in increased expression of CAAP1 mRNA CTD PMID:20977926 NCBI chr 5:109,313,253...109,414,323
Ensembl chr 5:109,361,912...109,414,314
JBrowse link
G Cacna1h calcium voltage-gated channel subunit alpha1 H decreases degradation ISO Bortezomib results in decreased degradation of CACNA1H protein CTD PMID:30552955 NCBI chr10:14,390,104...14,448,204
Ensembl chr10:14,390,113...14,448,376
JBrowse link
G Calr calreticulin multiple interactions
increases expression
ISO [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CALR mRNA]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; [Chloroquine co-treated with Bortezomib] promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; [Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein; [Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA; Bortezomib promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; Bortezomib results in increased expression of and affects the localization of CALR protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; DDIT3 protein affects the reaction [Bortezomib affects the localization of CALR protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; Doxorubicin promotes the reaction [Bortezomib affects the localization of CALR protein]
[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]]
CTD PMID:30482226 NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
JBrowse link
G Capn15 calpain 15 decreases expression ISO Bortezomib results in decreased expression of CAPN15 mRNA CTD PMID:20977926 NCBI chr10:14,972,807...14,999,411
Ensembl chr10:14,972,800...14,999,508
JBrowse link
G Card9 caspase recruitment domain family, member 9 multiple interactions ISO [arsenic trioxide co-treated with Bortezomib] results in increased expression of CARD9 mRNA CTD PMID:20471514 NCBI chr 3:9,171,814...9,180,310
Ensembl chr 3:9,171,815...9,180,237
JBrowse link
G Casp12 caspase 12 increases cleavage ISO Bortezomib results in increased cleavage of CASP12 protein CTD PMID:15509775 PMID:16357177 NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
JBrowse link
G Casp2 caspase 2 multiple interactions
increases response to substance
increases cleavage
ISO benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein]; Bortezomib promotes the reaction [Brefeldin A results in increased cleavage of and results in increased activity of CASP2 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein; Brefeldin A promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP2 protein]; CASP2 protein affects the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]
CASP2 results in increased susceptibility to Bortezomib
Bortezomib results in increased cleavage of CASP2 protein
CTD PMID:15509775 PMID:16446371 PMID:18723477 NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
JBrowse link
G Casp3 caspase 3 increases activity
increases cleavage
multiple interactions
increases expression
ISO Bortezomib results in increased activity of CASP3 protein
Bortezomib results in increased cleavage of CASP3 protein
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; [Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein; [Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [SCIO-469 co-treated with Bortezomib] results in increased activity of CASP3 protein; ATG5 gene mutant form inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]]; betulinic acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; betulinic acid inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]]; HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; [Arsenic Trioxide co-treated with Bortezomib] results in increased activity of CASP3 protein; [Arsenic Trioxide co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP3 protein; [Bortezomib co-treated with abexinostat] results in increased activity of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] affects the expression of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP3 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with Doxorubicin] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with oblimersen co-treated with Cyclophosphamide] results in increased activity of CASP3 protein; [Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP3 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP3 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP3 protein; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; [Cisplatin co-treated with Bortezomib] results in increased activity of CASP3 protein; [Dexamethasone co-treated with Bortezomib] results in increased activity of CASP3 protein; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of CASP3 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased activity of CASP3 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [Vorinostat co-treated with Bortezomib] results in increased activity of CASP3 protein; [Vorinostat co-treated with Bortezomib] results in increased cleavage of CASP3 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein]; BECN1 mutant form promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP3 protein]; betulinic acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; betulinic acid inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [gallium nitrate results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [NSC606985 results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of CASP3 protein]; Bortezomib promotes the reaction [Thapsigargin results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [Tunicamycin results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP3 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP3 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; MAPK14 mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP3 protein]; STK4 mutant form inhibits the reaction [Bortezomib results in increased activity of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP3 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased activity of CASP3 protein]; ZFAND2A protein inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein]
Bortezomib results in increased expression of CASP3 protein
CTD PMID:12393500 PMID:12893773 PMID:15070698 PMID:15173093 PMID:15509775 More... NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
JBrowse link
G Casp4 caspase 4 multiple interactions
increases response to substance
increases cleavage
increases activity
ISO [Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein; CASP4 protein results in increased susceptibility to [Cisplatin co-treated with Bortezomib]; PMAIP1 protein promotes the reaction [[Bortezomib co-treated with vorinostat] results in increased activity of CASP4 protein]; pyrazolanthrone inhibits the reaction [Bortezomib results in increased cleavage of CASP4 protein]
CASP4 protein results in increased susceptibility to Bortezomib
Bortezomib results in increased activity of CASP4 protein
CTD PMID:16357177 PMID:18641367 NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092
JBrowse link
G Casp6 caspase 6 multiple interactions
increases cleavage
ISO Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP6 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP6 protein] CTD PMID:16617327 PMID:17510429 NCBI chr 2:218,466,063...218,478,503
Ensembl chr 2:218,466,076...218,478,502
JBrowse link
G Casp7 caspase 7 multiple interactions
increases cleavage
increases activity
ISO [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP7 protein; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP7 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP7 protein; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP7 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP7 protein]
Bortezomib results in increased activity of CASP7 protein
CTD PMID:16024631 PMID:16617327 PMID:16904634 PMID:18342500 PMID:18534018 More... NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
JBrowse link
G Casp8 caspase 8 multiple interactions
increases cleavage
ISO [Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of CASP8 mRNA; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP8 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP8 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP8 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP8 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP8 protein; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of ATM protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of PRKDC protein]; [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased phosphorylation of TP53 protein]; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP8 protein; [IFNA2 protein co-treated with Bortezomib] results in increased activity of CASP8 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP8 protein; [Vorinostat co-treated with Bortezomib] results in increased cleavage of CASP8 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [abexinostat results in increased cleavage of CASP8 protein]; Bortezomib promotes the reaction [Arsenic Trioxide results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [TNFSF10 protein results in increased cleavage of CASP8 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP8 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP8 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP8 protein; CDKN1A protein affects the reaction [[TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP8 protein]; TNFRSF10B mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP8 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP8 protein] CTD PMID:12393500 PMID:12893773 PMID:12902978 PMID:15070698 PMID:15173093 More... NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
JBrowse link
G Casp9 caspase 9 multiple interactions
increases expression
increases response to substance
increases cleavage
ISO 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt affects the reaction [Bortezomib results in increased cleavage of CASP9 protein]; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in increased activity of CASP9 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased activity of CASP9 protein; [Bortezomib co-treated with Arsenic Trioxide] results in increased expression of CASP9 protein; [Bortezomib co-treated with Butyrates] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of CASP9 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib co-treated with Vorinostat] results in increased activity of CASP9 protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of and results in increased activity of CASP9 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of CASP9 protein; [gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein; [lonafarnib co-treated with Bortezomib] results in increased cleavage of CASP9 protein; [nutlin 3 co-treated with Bortezomib] results in increased activity of CASP9 protein; [trichostatin A co-treated with Bortezomib] results in increased cleavage of CASP9 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of CASP9 protein]; benzoylcarbonyl-valyl-aspartyl-valyl-alanyl-aspartyl-fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [[gambogic acid co-treated with Bortezomib] results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [abexinostat results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Arsenic Trioxide results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Butyrates results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [romidepsin results in increased cleavage of CASP9 protein]; Bortezomib promotes the reaction [Vorinostat results in increased activity of CASP9 protein]; Bortezomib promotes the reaction [ZFAND2A protein affects the cleavage of CASP9 protein]; Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein; CASP2 protein affects the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP9 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of CASP9 protein]; TNFSF10 protein promotes the reaction [Bortezomib results in increased cleavage of CASP9 protein]; ZFAND2A protein affects the reaction [Bortezomib results in increased cleavage of CASP9 protein]
Bortezomib results in increased expression of CASP9 protein
CASP9 gene SNP results in increased susceptibility to Bortezomib; CASP9 results in increased susceptibility to Bortezomib
CTD PMID:12893773 PMID:15070698 PMID:15173093 PMID:15509775 PMID:16024631 More... NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
JBrowse link
G Cbl Cbl proto-oncogene multiple interactions ISO [Bortezomib results in decreased activity of CBL protein] promotes the reaction [arsenic trioxide results in increased activity of AKT1 protein] CTD PMID:19457607 NCBI chr 8:44,487,824...44,571,620
Ensembl chr 8:44,489,410...44,571,176
JBrowse link
G Cbr3 carbonyl reductase 3 increases expression ISO [Bortezomib results in increased expression of NFE2L2 protein] which results in increased expression of CBR3 mRNA; Bortezomib results in increased expression of CBR3 mRNA CTD PMID:20806931 PMID:20977926 NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875
JBrowse link
G Cbx3 chromobox 3 increases expression ISO Bortezomib results in increased expression of CBX3 mRNA CTD PMID:20977926 NCBI chr 4:80,545,450...80,559,284
Ensembl chr 4:80,546,010...80,559,283
JBrowse link
G Ccar1 cell division cycle and apoptosis regulator 1 increases expression ISO Bortezomib results in increased expression of CCAR1 protein CTD PMID:21594647 PMID:21903591 NCBI chr20:30,685,916...30,728,531
Ensembl chr20:30,685,916...30,728,526
JBrowse link
G Ccdc186 coiled-coil domain containing 186 increases expression ISO Bortezomib results in increased expression of CCDC186 mRNA CTD PMID:20977926 NCBI chr 1:255,831,663...255,871,954
Ensembl chr 1:255,839,595...255,871,935
JBrowse link
G Ccdc32 coiled-coil domain containing 32 increases expression ISO Bortezomib results in increased expression of CCDC32 mRNA CTD PMID:20977926 NCBI chr 3:105,998,429...106,010,930
Ensembl chr 3:105,998,430...106,010,975
JBrowse link
G Ccdc6 coiled-coil domain containing 6 decreases expression ISO Bortezomib results in decreased expression of CCDC6 mRNA CTD PMID:20977926 NCBI chr20:18,432,177...18,528,186
Ensembl chr20:18,433,695...18,528,658
JBrowse link
G Ccdc82 coiled-coil domain containing 82 increases expression ISO Bortezomib results in increased expression of CCDC82 mRNA CTD PMID:20977926 NCBI chr 8:10,227,727...10,265,963
Ensembl chr 8:10,228,430...10,265,963
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 decreases expression ISO Bortezomib results in decreased expression of CCL2 mRNA CTD PMID:20471514 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
JBrowse link
G Ccl3 C-C motif chemokine ligand 3 increases expression
decreases expression
EXP
ISO
Bortezomib results in increased expression of CCL3 mRNA; Bortezomib results in increased expression of CCL3 protein
Bortezomib results in decreased expression of CCL3 mRNA
CTD PMID:18089816 PMID:20830808 NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
JBrowse link
G Ccnb1 cyclin B1 multiple interactions
increases expression
ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CCNB1 protein; Bortezomib results in increased ubiquitination of and results in increased expression of CCNB1 protein
Bortezomib results in increased expression of CCNB1 protein
CTD PMID:19074855 PMID:20367638 PMID:25522274 NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO [[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of CCND1 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of CCND1 protein; [Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of CCND1 protein; [geldanamycin co-treated with Bortezomib] results in decreased expression of CCND1 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of CCND1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of CCND1 protein] CTD PMID:12893773 PMID:15173093 PMID:15781649 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
JBrowse link
G Ccnd2 cyclin D2 decreases expression ISO Bortezomib results in decreased expression of CCND2 mRNA CTD PMID:20977926 NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
JBrowse link
G Ccnf cyclin F multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNF mRNA CTD PMID:25522274 NCBI chr10:13,253,073...13,279,140
Ensembl chr10:13,253,380...13,279,101
JBrowse link
G Ccng2 cyclin G2 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of CCNG2 mRNA CTD PMID:25522274 NCBI chr14:14,804,321...14,812,819
Ensembl chr14:14,804,322...14,812,830
JBrowse link
G Ccpg1 cell cycle progression 1 increases expression ISO Bortezomib results in increased expression of CCPG1 mRNA CTD PMID:20471514 PMID:20977926 NCBI chr 8:73,719,960...73,752,437
Ensembl chr 8:73,719,955...73,752,430
JBrowse link
G Cd27 CD27 molecule increases expression ISO Bortezomib results in increased expression of CD27 mRNA CTD PMID:17895889 NCBI chr 4:158,030,700...158,035,862
Ensembl chr 4:158,030,703...158,035,592
JBrowse link
G Cd38 CD38 molecule decreases expression ISO Bortezomib results in decreased expression of CD38 mRNA CTD PMID:20977926 NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986
JBrowse link
G Cd5 Cd5 molecule decreases expression ISO Bortezomib results in decreased expression of CD5 mRNA CTD PMID:20977926 NCBI chr 1:207,365,337...207,386,313
Ensembl chr 1:207,365,337...207,386,313
JBrowse link
G Cd69 Cd69 molecule increases expression ISO Bortezomib results in increased expression of CD69 mRNA CTD PMID:20977926 NCBI chr 4:162,725,446...162,733,364
Ensembl chr 4:162,725,446...162,733,542
JBrowse link
G Cd79a CD79a molecule decreases expression ISO Bortezomib results in decreased expression of CD79A mRNA CTD PMID:20977926 NCBI chr 1:80,493,520...80,497,936
Ensembl chr 1:80,493,581...80,497,935
JBrowse link
G Cd82 Cd82 molecule decreases expression ISO Bortezomib results in decreased expression of CD82 mRNA CTD PMID:20977926 NCBI chr 3:79,387,361...79,431,847
Ensembl chr 3:79,385,887...79,431,809
JBrowse link
G Cd9 CD9 molecule increases expression ISO Bortezomib results in increased expression of CD9 mRNA CTD PMID:20977926 NCBI chr 4:158,256,328...158,289,136
Ensembl chr 4:158,256,328...158,289,222
JBrowse link
G Cdc23 cell division cycle 23 increases expression ISO Bortezomib results in increased expression of CDC23 mRNA CTD PMID:20977926 NCBI chr18:26,236,891...26,260,611
Ensembl chr18:26,236,890...26,291,163
JBrowse link
G Cdc34 cell division cycle 34, ubiqiutin conjugating enzyme increases expression ISO Bortezomib results in increased expression of CDC34 mRNA CTD PMID:20977926 NCBI chr 7:10,017,588...10,023,586
Ensembl chr 7:10,017,588...10,023,186
JBrowse link
G Cdc37 cell division cycle 37, HSP90 cochaperone increases expression ISO Bortezomib results in increased expression of CDC37 mRNA CTD PMID:17895889 NCBI chr 8:19,677,400...19,690,761
Ensembl chr 8:19,671,938...19,690,809
JBrowse link
G Cdc42 cell division cycle 42 decreases expression ISO Bortezomib results in decreased expression of CDC42 mRNA CTD PMID:20977926 NCBI chr 5:149,555,069...149,593,239
Ensembl chr 5:149,553,724...149,593,111
JBrowse link
G Cdc42se2 CDC42 small effector 2 decreases expression ISO Bortezomib results in decreased expression of CDC42SE2 mRNA CTD PMID:20977926 NCBI chr10:38,836,549...38,905,056
Ensembl chr10:38,836,555...38,905,059
JBrowse link
G Cdk1 cyclin-dependent kinase 1 multiple interactions
increases phosphorylation
increases activity
decreases activity
ISO Bortezomib inhibits the reaction [docetaxel results in increased activity of CDK1 protein]
Bortezomib results in increased phosphorylation of CDK1 protein
Bortezomib results in increased activity of CDK1 protein
Bortezomib results in decreased activity of CDK1 protein
CTD PMID:14749476 PMID:16928825 PMID:19074855 PMID:20367638 NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408
JBrowse link
G Cdk2 cyclin dependent kinase 2 multiple interactions
decreases activity
ISO Bortezomib inhibits the reaction [docetaxel results in increased activity of CDK2 protein]
Bortezomib results in decreased activity of CDK2 protein
CTD PMID:14749476 NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases stability
multiple interactions
decreases response to substance
increases expression
ISO Bortezomib results in increased stability of CDKN1A protein
[Bortezomib co-treated with Butyrates] results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with Butyrates] results in increased expression of and results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with vorinostat] results in increased cleavage of CDKN1A protein; [Bortezomib co-treated with vorinostat] results in increased expression of and results in increased cleavage of CDKN1A protein; [TNFSF10 protein co-treated with Bortezomib] results in increased expression of CDKN1A protein; [trichostatin A co-treated with Bortezomib] results in increased expression of CDKN1A mRNA; [trichostatin A co-treated with Bortezomib] results in increased expression of CDKN1A protein; [vorinostat co-treated with Bortezomib] results in increased expression of CDKN1A protein; Bortezomib promotes the reaction [abexinostat results in increased expression of CDKN1A protein]; CDKN1A protein affects the reaction [[TNFSF10 protein co-treated with Bortezomib] results in increased cleavage of CASP8 protein]; CDKN1A results in decreased susceptibility to [Bortezomib co-treated with docetaxel]
CDKN1A results in decreased susceptibility to Bortezomib
Bortezomib results in increased expression of CDKN1A mRNA; Bortezomib results in increased expression of CDKN1A protein
CTD PMID:12893773 PMID:12902978 PMID:14749476 PMID:15173093 PMID:15543232 More... NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions
increases stability
increases expression
ISO [Bortezomib co-treated with Butyrates] results in increased cleavage of CDKN1B protein; [Bortezomib co-treated with Vorinostat] results in increased cleavage of CDKN1B protein; [Vorinostat co-treated with Bortezomib] results in increased expression of CDKN1B protein; Bortezomib promotes the reaction [Lapatinib results in increased expression of CDKN1B protein]; Cisplatin promotes the reaction [Bortezomib results in increased expression of CDKN1B protein]; Lapatinib promotes the reaction [Bortezomib results in increased expression of CDKN1B protein]
Bortezomib results in increased stability of CDKN1B protein
CTD PMID:14749476 PMID:15173093 PMID:15543232 PMID:18223318 PMID:18445700 More... NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
JBrowse link
G Cdt1 chromatin licensing and DNA replication factor 1 decreases expression ISO Bortezomib results in decreased expression of CDT1 mRNA CTD PMID:17659339 NCBI chr19:50,620,713...50,625,659
Ensembl chr19:50,620,713...50,625,659
JBrowse link
G Cebpa CCAAT/enhancer binding protein alpha multiple interactions ISO Bortezomib inhibits the reaction [NSC606985 results in decreased expression of CEBPA protein] CTD PMID:19662097 NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
JBrowse link
G Cebpb CCAAT/enhancer binding protein beta multiple interactions
increases expression
decreases expression
ISO
EXP
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CALR mRNA]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; [Chloroquine co-treated with Bortezomib] promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; [Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form; betulinic acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; betulinic acid inhibits the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; Bortezomib inhibits the reaction [Arsenic Trioxide results in decreased expression of CEBPB mRNA]; Bortezomib promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [Bortezomib results in increased expression of CALR mRNA]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; [Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form; betulinic acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; betulinic acid inhibits the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]]
Bortezomib results in decreased expression of CEBPB mRNA
CTD PMID:20471514 PMID:20830808 PMID:30482226 NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
JBrowse link
G Cenpc centromere protein C increases expression ISO Bortezomib results in increased expression of CENPC mRNA CTD PMID:20977926 NCBI chr14:21,988,067...22,046,732
Ensembl chr14:21,988,144...22,055,476
JBrowse link
G Cep290 centrosomal protein 290 increases expression ISO Bortezomib results in increased expression of CEP290 mRNA CTD PMID:20977926 NCBI chr 7:35,310,071...35,399,392
Ensembl chr 7:35,310,199...35,399,392
JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator affects expression
multiple interactions
decreases response to substance
decreases expression
increases expression
ISO Bortezomib affects the expression of CFLAR protein
[Bortezomib co-treated with TNFSF10 protein] results in decreased expression of CFLAR protein; [romidepsin co-treated with Bortezomib] results in decreased expression of CFLAR protein; TNFSF10 protein promotes the reaction [Bortezomib results in decreased expression of CFLAR protein]
CFLAR protein alternative form results in decreased susceptibility to Bortezomib; CFLAR results in decreased susceptibility to Bortezomib
Bortezomib results in decreased expression of CFLAR mRNA; Bortezomib results in decreased expression of CFLAR protein
Bortezomib results in increased expression of CFLAR protein; Bortezomib results in increased expression of CFLAR protein alternative form; Bortezomib results in increased expression of CFLAR protein modified form
CTD PMID:17326159 PMID:17327374 PMID:17351739 PMID:17510429 PMID:17659339 More... NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
JBrowse link
G Cgref1 cell growth regulator with EF hand domain 1 increases expression ISO Bortezomib results in increased expression of CGREF1 mRNA CTD PMID:17895889 NCBI chr 6:25,431,846...25,443,853
Ensembl chr 6:25,431,799...25,443,852
JBrowse link
G Chac1 ChaC glutathione-specific gamma-glutamylcyclotransferase 1 increases expression ISO Bortezomib results in increased expression of CHAC1 mRNA CTD PMID:15509775 NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526
JBrowse link
G Chaf1a chromatin assembly factor 1 subunit A decreases expression ISO Bortezomib results in decreased expression of CHAF1A mRNA CTD PMID:17659339 NCBI chr 9:873,953...900,701
Ensembl chr 9:874,051...900,654
JBrowse link
G Chd2 chromodomain helicase DNA binding protein 2 increases expression ISO Bortezomib results in increased expression of CHD2 mRNA CTD PMID:20977926 NCBI chr 1:127,188,146...127,317,041
Ensembl chr 1:127,190,059...127,300,502
JBrowse link
G Chfr checkpoint with forkhead and ring finger domains decreases expression ISO Bortezomib results in decreased expression of CHFR mRNA CTD PMID:20977926 NCBI chr12:46,504,497...46,538,104
Ensembl chr12:46,504,497...46,538,014
JBrowse link
G Chst11 carbohydrate sulfotransferase 11 decreases expression ISO Bortezomib results in decreased expression of CHST11 mRNA CTD PMID:20977926 NCBI chr 7:20,524,535...20,743,008
Ensembl chr 7:20,528,100...20,743,111
JBrowse link
G Chst2 carbohydrate sulfotransferase 2 decreases expression ISO Bortezomib results in decreased expression of CHST2 mRNA CTD PMID:20977926 NCBI chr 8:95,960,067...95,965,803
Ensembl chr 8:95,959,826...95,966,955
JBrowse link
G Chuk component of inhibitor of nuclear factor kappa B kinase complex increases expression
increases activity
ISO Bortezomib results in increased expression of CHUK mRNA
Bortezomib results in increased activity of CHUK protein
CTD PMID:20471514 PMID:24085292 NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
JBrowse link
G Cideb cell death-inducing DFFA-like effector b decreases expression ISO Bortezomib results in decreased expression of CIDEB mRNA CTD PMID:17659339 NCBI chr15:29,252,203...29,256,759
Ensembl chr15:29,252,213...29,256,605
JBrowse link
G Cilk1 ciliogenesis associated kinase 1 increases expression ISO Bortezomib results in increased expression of CILK1 mRNA CTD PMID:20977926 NCBI chr 8:78,984,075...79,042,695
Ensembl chr 8:78,984,258...79,042,691
JBrowse link
G Clec7a C-type lectin domain containing 7A increases expression ISO Bortezomib results in increased expression of CLEC7A mRNA CTD PMID:20977926 NCBI chr 4:162,902,731...162,913,931
Ensembl chr 4:162,902,732...162,913,897
JBrowse link
G Clip4 CAP-GLY domain containing linker protein family, member 4 increases expression ISO Bortezomib results in increased expression of CLIP4 mRNA CTD PMID:20977926 NCBI chr 6:23,616,280...23,697,625
Ensembl chr 6:23,616,281...23,677,874
JBrowse link
G Cln6 CLN6, transmembrane ER protein decreases expression ISO Bortezomib results in decreased expression of CLN6 mRNA CTD PMID:20977926 NCBI chr 8:63,303,356...63,318,360
Ensembl chr 8:63,303,029...63,318,360
JBrowse link
G Clptm1 CLPTM1 regulator of GABA type A receptor forward trafficking decreases expression ISO Bortezomib results in decreased expression of CLPTM1 mRNA CTD PMID:20977926 NCBI chr 1:79,289,478...79,321,079
Ensembl chr 1:79,289,477...79,321,092
JBrowse link
G Clu clusterin increases expression ISO Bortezomib results in increased expression of CLU mRNA CTD PMID:20977926 NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
JBrowse link
G Cox8a cytochrome c oxidase subunit 8A decreases expression ISO Bortezomib results in decreased expression of COX8A mRNA CTD PMID:30818834 NCBI chr 1:204,402,118...204,404,439 JBrowse link
G Cpt1c carnitine palmitoyltransferase 1c increases response to substance ISO CPT1C gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr 1:95,442,814...95,457,347
Ensembl chr 1:95,442,817...95,457,342
JBrowse link
G Crebbp CREB binding protein decreases expression ISO Bortezomib results in decreased expression of CREBBP mRNA CTD PMID:25913414 NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888
JBrowse link
G Crem cAMP responsive element modulator increases expression ISO Bortezomib results in increased expression of CREM mRNA CTD PMID:20977926 NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989
JBrowse link
G Crip2 cysteine-rich protein 2 decreases expression ISO Bortezomib results in decreased expression of CRIP2 mRNA CTD PMID:20977926 NCBI chr 6:132,221,120...132,226,066
Ensembl chr 6:132,221,082...132,226,065
JBrowse link
G Crkl CRK like proto-oncogene, adaptor protein multiple interactions ISO [alvocidib co-treated with Bortezomib co-treated with ABL1] results in decreased phosphorylation of CRKL protein CTD PMID:15039284 NCBI chr11:83,528,788...83,563,214
Ensembl chr11:83,526,530...83,563,238
JBrowse link
G Cryab crystallin, alpha B multiple interactions
increases expression
ISO
EXP
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CRYAB mRNA
Bortezomib results in increased expression of CRYAB mRNA
CTD PMID:20830808 PMID:25522274 NCBI chr 8:51,093,441...51,099,161
Ensembl chr 8:51,093,441...51,099,157
JBrowse link
G Cst7 cystatin F increases expression ISO Bortezomib results in increased expression of CST7 mRNA CTD PMID:20977926 NCBI chr 3:139,396,830...139,405,557
Ensembl chr 3:139,396,850...139,405,557
JBrowse link
G Ctdspl2 CTD small phosphatase like 2 decreases expression ISO Bortezomib results in decreased expression of CTDSPL2 mRNA CTD PMID:20977926 NCBI chr 3:108,914,650...108,970,620
Ensembl chr 3:108,915,280...108,967,227
JBrowse link
G Cth cystathionine gamma-lyase multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of CTH mRNA CTD PMID:25522274 NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234
JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions
decreases response to substance
increases expression
ISO 2-methoxyestradiol inhibits the reaction [CTNNB1 protein results in decreased susceptibility to Bortezomib]; arsenic trioxide inhibits the reaction [CTNNB1 protein results in decreased susceptibility to Bortezomib]; TNFSF10 protein inhibits the reaction [Bortezomib results in increased expression of CTNNB1 protein] CTD PMID:18485479 PMID:19100720 NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
JBrowse link
G Ctsb cathepsin B multiple interactions
increases localization
ISO 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased localization of CTSB protein] CTD PMID:16446371 NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
JBrowse link
G Ctsd cathepsin D increases expression ISO Bortezomib results in increased expression of CTSD mRNA CTD PMID:20977926 NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
JBrowse link
G Cul1 cullin 1 increases expression ISO Bortezomib results in increased expression of CUL1 mRNA CTD PMID:17895889 NCBI chr 4:76,551,952...76,625,830
Ensembl chr 4:76,551,983...76,627,980
JBrowse link
G Cul3 cullin 3 decreases expression ISO Bortezomib results in decreased expression of CUL3 mRNA CTD PMID:17659339 NCBI chr 9:81,592,641...81,670,428
Ensembl chr 9:81,592,641...81,670,462
JBrowse link
G Cwf19l1 CWF19 like cell cycle control factor 1 decreases expression ISO Bortezomib results in decreased expression of CWF19L1 mRNA CTD PMID:20977926 NCBI chr 1:242,997,720...243,020,989
Ensembl chr 1:242,997,726...243,020,961
JBrowse link
G Cxcl1 C-X-C motif chemokine ligand 1 increases expression ISO Bortezomib results in increased expression of CXCL1 mRNA CTD PMID:15509775 NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
JBrowse link
G Cxcl2 C-X-C motif chemokine ligand 2 increases expression
multiple interactions
ISO
EXP
Bortezomib results in increased expression of CXCL2 mRNA
Bortezomib results in increased expression of CXCL2 mRNA; Bortezomib results in increased expression of CXCL2 protein
Bortezomib inhibits the reaction [Fluorouracil results in increased expression of CXCL2 mRNA]
CTD PMID:20830808 PMID:27194111 NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
JBrowse link
G Cxcl3 C-X-C motif chemokine ligand 3 multiple interactions
increases expression
ISO Bortezomib inhibits the reaction [Fluorouracil results in increased expression of CXCL1 mRNA]
Bortezomib results in increased expression of CXCL1 mRNA
CTD PMID:15509775 PMID:27194111 NCBI chr14:17,270,146...17,289,458
Ensembl chr14:17,270,146...17,289,511
JBrowse link
G Cxcr4 C-X-C motif chemokine receptor 4 decreases expression ISO Bortezomib results in decreased expression of CXCR4 mRNA CTD PMID:20977926 NCBI chr13:40,077,976...40,081,883
Ensembl chr13:40,077,976...40,081,883
JBrowse link
G Cyb5r1 cytochrome b5 reductase 1 increases expression ISO Bortezomib results in increased expression of CYB5R1 mRNA CTD PMID:20977926 NCBI chr13:45,849,017...45,855,458
Ensembl chr13:45,849,091...45,855,458
JBrowse link
G Cyba cytochrome b-245 alpha chain decreases expression ISO Bortezomib results in decreased expression of CYBA mRNA CTD PMID:20977926 NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
JBrowse link
G Cycs cytochrome c, somatic multiple interactions
affects localization
ISO [Bortezomib co-treated with Butyrates] affects the localization of CYCS protein; [Bortezomib co-treated with vorinostat] affects the localization of CYCS protein
Bortezomib affects the localization of CYCS protein
CTD PMID:12893773 PMID:16024631 NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
JBrowse link
G Cyp1a2 cytochrome P450, family 1, subfamily a, polypeptide 2 affects metabolic processing ISO CYP1A2 protein affects the metabolism of Bortezomib CTD PMID:15764713 NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
JBrowse link
G Cyp2c6v1 cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 affects metabolic processing ISO CYP2C19 protein affects the metabolism of Bortezomib CTD PMID:15764713 NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 affects metabolic processing ISO CYP2D6 protein affects the metabolism of Bortezomib CTD PMID:15764713 NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
JBrowse link
G Cyp2u1 cytochrome P450, family 2, subfamily u, polypeptide 1 increases expression ISO Bortezomib results in increased expression of CYP2U1 mRNA CTD PMID:20977926 NCBI chr 2:219,849,403...219,866,959
Ensembl chr 2:219,849,407...219,866,882
JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 affects metabolic processing ISO CYP3A4 protein affects the metabolism of Bortezomib CTD PMID:15764713 NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
JBrowse link
G Cytip cytohesin 1 interacting protein increases expression ISO Bortezomib results in increased expression of CYTIP mRNA CTD PMID:20977926 NCBI chr 3:42,698,058...42,774,955
Ensembl chr 3:42,698,768...42,725,993
JBrowse link
G Dap3 death associated protein 3 increases expression ISO Bortezomib results in increased expression of DAP3 mRNA CTD PMID:17659339 NCBI chr 2:174,319,341...174,347,489
Ensembl chr 2:174,318,983...174,346,461
JBrowse link
G Dapk2 death-associated protein kinase 2 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DAPK2 mRNA CTD PMID:25522274 NCBI chr 8:66,706,536...66,825,567
Ensembl chr 8:66,706,609...66,825,567
JBrowse link
G Dazap2 DAZ associated protein 2 decreases expression ISO Bortezomib results in decreased expression of DAZAP2 mRNA CTD PMID:20977926 NCBI chr 7:131,714,723...131,720,266
Ensembl chr 7:131,714,745...131,720,265
JBrowse link
G Dbn1 drebrin 1 increases expression ISO Bortezomib results in increased expression of DBN1 mRNA CTD PMID:20977926 NCBI chr17:9,150,608...9,164,982
Ensembl chr17:9,150,659...9,164,984
JBrowse link
G Dcaf11 DDB1 and CUL4 associated factor 11 decreases expression ISO Bortezomib results in decreased expression of DCAF11 mRNA CTD PMID:20977926 NCBI chr15:29,046,744...29,057,450
Ensembl chr15:29,046,826...29,057,669
JBrowse link
G Dcaf13 DDB1 and CUL4 associated factor 13 increases expression ISO Bortezomib results in increased expression of DCAF13 mRNA CTD PMID:20977926 NCBI chr 7:70,160,983...70,196,142
Ensembl chr 7:70,160,941...70,196,142
JBrowse link
G Dcps decapping enzyme, scavenger decreases expression ISO Bortezomib results in decreased expression of DCPS mRNA CTD PMID:20977926 NCBI chr 8:33,468,669...33,524,407 JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions
increases expression
decreases response to substance
ISO
EXP
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein; betulinic acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; betulinic acid inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; Bortezomib inhibits the reaction [Tunicamycin results in increased expression of DDIT3 protein]; Bortezomib promotes the reaction [gambogic acid results in increased expression of DDIT3 protein]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [Bortezomib affects the localization of CALR protein]; DDIT3 protein affects the reaction [Bortezomib results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; gambogic acid promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Nitroprusside promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]
Bortezomib results in increased expression of DDIT3 mRNA; Bortezomib results in increased expression of DDIT3 protein
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein; [Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein; betulinic acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; betulinic acid inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]; Bortezomib inhibits the reaction [1,2-dithiol-3-thione inhibits the reaction [Tunicamycin results in increased expression of DDIT3 mRNA]]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [Bortezomib results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]]; Nitroprusside inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Nitroprusside inhibits the reaction [Bortezomib results in increased expression of DDIT3 protein]
DDIT3 results in decreased susceptibility to Bortezomib
CTD PMID:15509775 PMID:16024631 PMID:16357177 PMID:17659339 PMID:17709599 More... NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
JBrowse link
G Ddx11 DEAD/H-box helicase 11 decreases expression ISO Bortezomib results in decreased expression of DDX11 mRNA CTD PMID:20977926 NCBI chr 9:105,833,234...105,862,844
Ensembl chr 9:105,833,504...105,862,550
JBrowse link
G Deaf1 DEAF1 transcription factor decreases expression ISO Bortezomib results in decreased expression of DEAF1 mRNA CTD PMID:20977926 NCBI chr 1:196,401,857...196,435,541
Ensembl chr 1:196,401,857...196,435,541
JBrowse link
G Dedd2 death effector domain containing 2 increases expression ISO Bortezomib results in increased expression of DEDD2 mRNA CTD PMID:17659339 NCBI chr 1:80,789,084...80,807,789
Ensembl chr 1:80,792,000...80,807,714
JBrowse link
G Def6 DEF6 guanine nucleotide exchange factor decreases expression ISO Bortezomib results in decreased expression of DEF6 mRNA CTD PMID:20977926 NCBI chr20:6,268,614...6,290,030
Ensembl chr20:6,268,601...6,289,961
JBrowse link
G Dennd4a DENN domain containing 4A increases expression ISO Bortezomib results in increased expression of DENND4A mRNA CTD PMID:20977926 NCBI chr 8:65,322,920...65,436,331
Ensembl chr 8:65,322,941...65,436,330
JBrowse link
G Dennd4b DENN domain containing 4B increases expression ISO Bortezomib results in increased expression of DENND4B mRNA CTD PMID:15509775 NCBI chr 2:175,720,473...175,736,425
Ensembl chr 2:175,709,610...175,736,426
JBrowse link
G Dennd4c DENN domain containing 4C increases expression ISO Bortezomib results in increased expression of DENND4C mRNA CTD PMID:20977926 NCBI chr 5:101,272,298...101,369,529
Ensembl chr 5:101,272,005...101,368,118
JBrowse link
G Dgke diacylglycerol kinase epsilon decreases expression ISO Bortezomib results in decreased expression of DGKE mRNA CTD PMID:20977926 NCBI chr10:73,852,679...73,877,334
Ensembl chr10:73,855,583...73,877,100
JBrowse link
G Diablo diablo, IAP-binding mitochondrial protein affects localization
increases localization
increases expression
multiple interactions
ISO Bortezomib affects the localization of DIABLO protein
Bortezomib results in increased localization of DIABLO protein
Bortezomib results in increased expression of DIABLO mRNA; Bortezomib results in increased expression of DIABLO protein
[alvocidib co-treated with Bortezomib] results in increased secretion of DIABLO protein; [Bortezomib co-treated with 1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazole] results in decreased localization of DIABLO protein; [Bortezomib co-treated with Butyrates] affects the localization of DIABLO protein; [Bortezomib co-treated with TNFSF10 protein] results in increased expression of DIABLO protein; [Bortezomib co-treated with vorinostat] affects the localization of DIABLO protein; Bortezomib inhibits the reaction [BAX mutant form inhibits the reaction [TNFSF10 protein results in increased localization of DIABLO protein]]; Bortezomib promotes the reaction [TNFSF10 protein results in increased localization of DIABLO protein]
CTD PMID:12893773 PMID:12902978 PMID:14555532 PMID:15039284 PMID:15070698 More... NCBI chr12:33,055,784...33,070,400
Ensembl chr12:33,055,263...33,070,387
JBrowse link
G Dlgap5 DLG associated protein 5 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of DLGAP5 mRNA CTD PMID:25522274 NCBI chr15:20,633,964...20,664,569
Ensembl chr15:20,633,966...20,664,518
JBrowse link
G Dnaaf5 dynein, axonemal, assembly factor 5 decreases expression ISO Bortezomib results in decreased expression of DNAAF5 mRNA CTD PMID:20977926 NCBI chr12:15,453,636...15,492,722
Ensembl chr12:15,453,636...15,492,739
JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 increases expression ISO Bortezomib results in increased expression of DNAJB1 mRNA CTD PMID:15509775 NCBI chr19:24,522,717...24,526,458
Ensembl chr19:24,522,717...24,526,458
JBrowse link
G Dnajc14 DnaJ heat shock protein family (Hsp40) member C14 decreases expression ISO Bortezomib results in decreased expression of DNAJC14 mRNA CTD PMID:20977926 NCBI chr 7:1,233,856...1,247,349
Ensembl chr 7:1,235,162...1,248,645
JBrowse link
G Dnajc4 DnaJ heat shock protein family (Hsp40) member C4 decreases expression ISO Bortezomib results in decreased expression of DNAJC4 mRNA CTD PMID:20977926 NCBI chr 1:204,178,189...204,182,412
Ensembl chr 1:204,178,191...204,182,387
JBrowse link
G Dnm2 dynamin 2 decreases expression ISO Bortezomib results in decreased expression of DNM2 mRNA CTD PMID:20977926 NCBI chr 8:19,978,313...20,060,162
Ensembl chr 8:19,978,400...20,060,157
JBrowse link
G Dpy19l4 dpy-19 like 4 increases expression ISO Bortezomib results in increased expression of DPY19L4 mRNA CTD PMID:20977926 NCBI chr 5:24,351,289...24,410,932
Ensembl chr 5:24,353,900...24,410,912
JBrowse link
G Dst dystonin increases expression ISO Bortezomib results in increased expression of DST mRNA CTD PMID:17659339 NCBI chr 9:36,135,657...36,529,617
Ensembl chr 9:36,135,284...36,529,615
JBrowse link
G Dusp15 dual specificity phosphatase 15 decreases expression ISO Bortezomib results in decreased expression of DUSP15 mRNA CTD PMID:20977926 NCBI chr 3:141,408,495...141,419,137
Ensembl chr 3:141,408,498...141,418,999
JBrowse link
G Dusp4 dual specificity phosphatase 4 decreases expression ISO Bortezomib results in decreased expression of DUSP4 mRNA CTD PMID:20977926 NCBI chr16:57,376,659...57,398,161
Ensembl chr16:57,377,229...57,398,138
JBrowse link
G Dusp5 dual specificity phosphatase 5 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of DUSP5 mRNA CTD PMID:25522274 NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818
JBrowse link
G Dync1i1 dynein cytoplasmic 1 intermediate chain 1 increases expression ISO Bortezomib results in increased expression of DYNC1I1 mRNA CTD PMID:20977926 NCBI chr 4:33,852,597...34,166,159
Ensembl chr 4:33,852,927...34,166,149
JBrowse link
G E2f1 E2F transcription factor 1 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased activity of E2F1 protein CTD PMID:25522274 NCBI chr 3:143,064,535...143,075,362 JBrowse link
G Ecpas Ecm29 proteasome adaptor and scaffold increases expression ISO Bortezomib results in increased expression of ECPAS mRNA CTD PMID:20977926 NCBI chr 5:73,601,745...73,714,026
Ensembl chr 5:73,604,533...73,713,860
JBrowse link
G Edaradd EDAR-associated death domain increases expression ISO Bortezomib results in increased expression of EDARADD mRNA CTD PMID:17895889 NCBI chr17:85,866,629...85,910,612
Ensembl chr17:85,656,905...85,910,447
JBrowse link
G Egln3 egl-9 family hypoxia-inducible factor 3 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of EGLN3 mRNA CTD PMID:25522274 NCBI chr 6:71,650,297...71,675,766
Ensembl chr 6:71,650,297...71,675,766
JBrowse link
G Egr1 early growth response 1 increases expression ISO Bortezomib results in increased expression of EGR1 mRNA CTD PMID:20471514 NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
JBrowse link
G Egr2 early growth response 2 decreases expression ISO
EXP
Bortezomib results in decreased expression of EGR2 mRNA
Bortezomib results in decreased expression of EGR2 mRNA; Bortezomib results in decreased expression of EGR2 protein
CTD PMID:20830808 NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562
JBrowse link
G Ehmt2 euchromatic histone lysine methyltransferase 2 decreases expression ISO Bortezomib results in decreased expression of EHMT2 mRNA CTD PMID:20977926 NCBI chr20:3,919,623...3,936,751
Ensembl chr20:3,919,624...3,941,547
JBrowse link
G Eif1 eukaryotic translation initiation factor 1 increases expression ISO Bortezomib results in increased expression of EIF1 mRNA CTD PMID:20977926 NCBI chr10:85,246,751...85,248,842
Ensembl chr10:85,246,764...85,427,327
JBrowse link
G Eif2a eukaryotic translation initiation factor 2A decreases phosphorylation ISO Bortezomib results in decreased phosphorylation of EIF2A protein CTD PMID:18641367 NCBI chr 2:142,761,303...142,794,767
Ensembl chr 2:142,761,416...142,795,068
JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 increases phosphorylation
multiple interactions
decreases response to substance
ISO Bortezomib results in increased phosphorylation of EIF2AK3 protein
Bortezomib inhibits the reaction [1,2-dithiol-3-thione inhibits the reaction [Tunicamycin results in increased expression of EIF2AK3 mRNA]]
EIF2AK3 mutant form inhibits the reaction [Bortezomib results in increased phosphorylation of EIF2S1 protein]
EIF2AK3 results in decreased susceptibility to Bortezomib
CTD PMID:15509775 PMID:16928686 PMID:20022965 PMID:22959925 NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha multiple interactions
increases phosphorylation
ISO Bortezomib inhibits the reaction [Tunicamycin results in increased phosphorylation of EIF2S1 protein]; EIF2AK3 mutant form inhibits the reaction [Bortezomib results in increased phosphorylation of EIF2S1 protein] CTD PMID:16357177 PMID:20022965 PMID:21090173 NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
JBrowse link
G Eif2s3 eukaryotic translation initiation factor 2 subunit gamma decreases expression ISO Bortezomib results in decreased expression of EIF2S3 mRNA CTD PMID:20977926 NCBI chr  X:58,916,513...58,939,923
Ensembl chr  X:58,917,490...58,940,686
JBrowse link
G Eif4ebp1 eukaryotic translation initiation factor 4E binding protein 1 multiple interactions ISO [trichostatin A co-treated with Bortezomib] results in decreased phosphorylation of EIF4EBP1 protein CTD PMID:21345073 NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
JBrowse link
G Eif5a eukaryotic translation initiation factor 5A decreases expression ISO Bortezomib results in decreased expression of EIF5A mRNA CTD PMID:20977926 NCBI chr10:54,640,104...54,644,845
Ensembl chr10:54,640,024...54,644,656
JBrowse link
G Elp5 elongator acetyltransferase complex subunit 5 decreases expression ISO Bortezomib results in decreased expression of ELP5 mRNA CTD PMID:20977926 NCBI chr10:54,692,526...54,704,255
Ensembl chr10:54,692,530...54,704,923
JBrowse link
G Eno2 enolase 2 increases expression ISO Bortezomib results in increased expression of ENO2 mRNA CTD PMID:20977926 NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
JBrowse link
G Epha1 Eph receptor A1 decreases expression ISO Bortezomib results in decreased expression of EPHA1 mRNA CTD PMID:20977926 NCBI chr 4:71,246,409...71,260,920
Ensembl chr 4:71,246,409...71,260,846
JBrowse link
G Ephb2 Eph receptor B2 decreases expression ISO Bortezomib results in decreased expression of EPHB2 mRNA CTD PMID:20977926 NCBI chr 5:148,889,574...149,077,027
Ensembl chr 5:148,897,246...149,077,059
JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 multiple interactions
decreases phosphorylation
ISO Bortezomib promotes the reaction [lapatinib results in decreased phosphorylation of ERBB2 protein]; lapatinib promotes the reaction [Bortezomib results in decreased phosphorylation of ERBB2 protein] CTD PMID:20701607 NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
JBrowse link
G Ercc3 ERCC excision repair 3, TFIIH core complex helicase subunit increases response to substance ISO ERCC3 gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr18:23,883,613...23,914,326
Ensembl chr18:23,883,580...23,914,329
JBrowse link
G Ercc4 ERCC excision repair 4, endonuclease catalytic subunit increases response to substance ISO ERCC4 gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr10:2,416,259...2,448,364 JBrowse link
G Erlin2 ER lipid raft associated 2 decreases expression ISO Bortezomib results in decreased expression of ERLIN2 mRNA CTD PMID:20977926 NCBI chr16:65,017,654...65,034,184
Ensembl chr16:65,018,532...65,033,671
JBrowse link
G Ern1 endoplasmic reticulum to nucleus signaling 1 multiple interactions
decreases response to substance
ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of ERN1 mRNA
ERN1 results in decreased susceptibility to Bortezomib
CTD PMID:16357177 PMID:25522274 NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
JBrowse link
G Esf1 ESF1 nucleolar pre-rRNA processing protein homolog increases expression ISO Bortezomib results in increased expression of ESF1 mRNA CTD PMID:20977926 NCBI chr 3:127,454,744...127,507,941
Ensembl chr 3:127,454,811...127,507,817
JBrowse link
G Esr1 estrogen receptor 1 multiple interactions ISO Bortezomib binds to and results in decreased activity of ESR1 protein; Bortezomib inhibits the reaction [Estradiol results in increased activity of ESR1 protein] CTD PMID:25752796 PMID:30818834 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
JBrowse link
G Esr2 estrogen receptor 2 multiple interactions ISO [Arsenic Trioxide co-treated with Bortezomib] results in decreased expression of ESR2 mRNA; Bortezomib binds to and results in decreased activity of ESR2 protein; Bortezomib inhibits the reaction [Estradiol results in increased activity of ESR2 protein] CTD PMID:25752796 PMID:25913414 PMID:30818834 NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
JBrowse link
G Esrra estrogen related receptor, alpha decreases expression
multiple interactions
ISO Bortezomib results in decreased expression of ESRRA mRNA
Bortezomib inhibits the reaction [PPARGC1A protein results in increased activity of ESRRA protein]; Bortezomib inhibits the reaction [XCT790 results in decreased activity of ESRRA protein]
CTD PMID:20977926 PMID:30818834 NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268
JBrowse link
G Esyt2 extended synaptotagmin 2 decreases expression ISO Bortezomib results in decreased expression of ESYT2 mRNA CTD PMID:20977926 NCBI chr 6:137,219,653...137,312,590
Ensembl chr 6:137,219,707...137,312,590
JBrowse link
G Etv4 ETS variant transcription factor 4 decreases expression ISO Bortezomib results in decreased expression of ETV4 mRNA CTD PMID:20977926 NCBI chr10:86,706,749...86,721,974
Ensembl chr10:86,706,749...86,721,974
JBrowse link
G F2rl1 F2R like trypsin receptor 1 decreases expression ISO Bortezomib results in decreased expression of F2RL1 mRNA CTD PMID:20977926 NCBI chr 2:26,772,274...26,785,226
Ensembl chr 2:26,772,278...26,785,226
JBrowse link
G F3 coagulation factor III, tissue factor increases expression
multiple interactions
ISO Bortezomib results in increased expression of F3 protein
[Dexamethasone co-treated with lenalidomide co-treated with Bortezomib] results in increased expression of F3 mRNA; [Dexamethasone co-treated with lenalidomide co-treated with Bortezomib] results in increased expression of F3 protein
CTD PMID:23696885 NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
JBrowse link
G Fads2 fatty acid desaturase 2 decreases expression ISO Bortezomib results in decreased expression of FADS2 mRNA CTD PMID:20977926 NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
JBrowse link
G Faf1 Fas associated factor 1 increases expression ISO Bortezomib results in increased expression of FAF1 mRNA CTD PMID:17895889 NCBI chr 5:124,426,032...124,790,014
Ensembl chr 5:124,426,062...124,789,977
JBrowse link
G Fam118b family with sequence similarity 118, member B increases expression ISO Bortezomib results in increased expression of FAM118B mRNA CTD PMID:20977926 NCBI chr 8:33,566,681...33,617,310
Ensembl chr 8:33,566,669...33,617,270
JBrowse link
G Fam168a family with sequence similarity 168, member A increases expression ISO Bortezomib results in increased expression of FAM168A mRNA CTD PMID:20977926 NCBI chr 1:155,057,352...155,203,439
Ensembl chr 1:155,057,352...155,201,220
JBrowse link
G Fam20b FAM20B, glycosaminoglycan xylosylkinase decreases expression ISO Bortezomib results in decreased expression of FAM20B mRNA CTD PMID:20977926 NCBI chr13:68,801,663...68,839,979
Ensembl chr13:68,801,669...68,839,915
JBrowse link
G Fam219a family with sequence similarity 219, member A increases expression ISO Bortezomib results in increased expression of FAM219A mRNA CTD PMID:20977926 NCBI chr 5:56,679,272...56,729,959
Ensembl chr 5:56,680,613...56,729,924
JBrowse link
G Fam241b family with sequence similarity 241 member B increases expression ISO Bortezomib results in increased expression of FAM241B mRNA CTD PMID:20977926 NCBI chr20:30,052,315...30,055,247
Ensembl chr20:30,052,324...30,055,084
JBrowse link
G Fam43a family with sequence similarity 43, member A decreases expression ISO Bortezomib results in decreased expression of FAM43A mRNA CTD PMID:20977926 NCBI chr11:70,128,253...70,131,401
Ensembl chr11:70,128,253...70,131,401
JBrowse link
G Fam76a family with sequence similarity 76, member A increases expression ISO Bortezomib results in increased expression of FAM76A mRNA CTD PMID:20977926 NCBI chr 5:145,107,491...145,135,734
Ensembl chr 5:145,107,491...145,135,574
JBrowse link
G Fancd2 FA complementation group D2 decreases expression ISO Bortezomib results in decreased expression of FANCD2 mRNA; Bortezomib results in decreased expression of FANCD2 protein CTD PMID:19934314 PMID:21917757 NCBI chr 4:146,679,014...146,743,422
Ensembl chr 4:146,679,179...146,743,412
JBrowse link
G Farsa phenylalanyl-tRNA synthetase subunit alpha decreases expression ISO Bortezomib results in decreased expression of FARSA mRNA CTD PMID:20977926 NCBI chr19:23,291,409...23,300,985
Ensembl chr19:23,268,869...23,300,980
JBrowse link
G Fas Fas cell surface death receptor multiple interactions
decreases expression
increases expression
ISO [Bortezomib co-treated with vorinostat] results in increased expression of FAS protein
Bortezomib results in decreased expression of FAS mRNA
Bortezomib results in increased expression of FAS mRNA; Bortezomib results in increased expression of FAS protein
CTD PMID:17351739 PMID:20471514 PMID:25913414 NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
JBrowse link
G Faslg Fas ligand multiple interactions
increases expression
ISO [Bortezomib co-treated with vorinostat] results in increased expression of FASLG mRNA; [Bortezomib co-treated with vorinostat] results in increased expression of FASLG protein; Bortezomib promotes the reaction [arsenic trioxide results in increased activity of FASLG]; Curcumin inhibits the reaction [[vorinostat co-treated with Bortezomib] results in increased expression of FASLG protein]
Bortezomib results in increased expression of FASLG protein
CTD PMID:17351739 PMID:20471514 NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
JBrowse link
G Fastk Fas-activated serine/threonine kinase decreases expression ISO Bortezomib results in decreased expression of FASTK mRNA CTD PMID:20977926 NCBI chr 4:10,732,273...10,736,332
Ensembl chr 4:10,732,256...10,737,430
JBrowse link
G Fbln5 fibulin 5 decreases expression ISO Bortezomib results in decreased expression of FBLN5 mRNA CTD PMID:20977926 NCBI chr 6:120,899,219...120,977,829
Ensembl chr 6:120,899,224...120,977,755
JBrowse link
G Fbxw7 F-box and WD repeat domain containing 7 decreases expression ISO Bortezomib results in decreased expression of FBXW7 mRNA CTD PMID:20977926 NCBI chr 2:170,150,552...170,310,698
Ensembl chr 2:170,149,694...170,309,941
JBrowse link
G Fgf21 fibroblast growth factor 21 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of FGF21 mRNA CTD PMID:25522274 NCBI chr 1:96,083,495...96,084,738
Ensembl chr 1:96,083,441...96,090,454
JBrowse link
G Fgfr1op2 FGFR1 oncogene partner 2 increases expression ISO Bortezomib results in increased expression of FGFR1OP2 mRNA CTD PMID:20977926 NCBI chr 4:179,491,602...179,512,630
Ensembl chr 4:179,491,599...179,512,630
JBrowse link
G Fkbp1a FKBP prolyl isomerase 1A decreases expression ISO Bortezomib results in decreased expression of FKBP1A mRNA CTD PMID:20977926 NCBI chr 3:140,040,359...140,060,107
Ensembl chr 3:140,040,278...140,060,743
JBrowse link
G Fkbp5 FKBP prolyl isomerase 5 decreases expression ISO Bortezomib results in decreased expression of FKBP5 mRNA CTD PMID:20977926 NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674
JBrowse link
G Flcn folliculin increases expression ISO Bortezomib results in increased expression of FLCN mRNA CTD PMID:20977926 NCBI chr10:44,588,621...44,607,808
Ensembl chr10:44,588,624...44,607,769
JBrowse link
G Fmr1 FMRP translational regulator 1 decreases expression ISO Bortezomib results in decreased expression of FMR1 mRNA CTD PMID:17659339 NCBI chr  X:147,240,239...147,278,057
Ensembl chr  X:147,240,301...147,278,050
JBrowse link
G Folr1 folate receptor alpha decreases expression ISO Bortezomib results in decreased expression of FOLR1 mRNA CTD PMID:20977926 NCBI chr 1:156,219,460...156,238,436
Ensembl chr 1:156,219,460...156,230,667
JBrowse link
G Foxa1 forkhead box A1 multiple interactions
decreases expression
ISO [arsenic trioxide co-treated with Bortezomib] results in increased expression of FOXA1 mRNA
Bortezomib results in decreased expression of FOXA1 mRNA
CTD PMID:20471514 PMID:25913414 NCBI chr 6:75,099,907...75,136,534
Ensembl chr 6:75,103,503...75,136,188
JBrowse link
G Fry FRY microtubule binding protein increases expression ISO Bortezomib results in increased expression of FRY mRNA CTD PMID:20977926 NCBI chr12:4,493,890...4,887,118
Ensembl chr12:4,493,891...4,799,116
JBrowse link
G Fsd1l fibronectin type III and SPRY domain containing 1-like increases expression ISO Bortezomib results in increased expression of FSD1L mRNA CTD PMID:20977926 NCBI chr 5:68,258,877...68,334,931
Ensembl chr 5:68,258,932...68,334,928
JBrowse link
G Fzd2 frizzled class receptor 2 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of FZD2 mRNA CTD PMID:25522274 NCBI chr10:87,561,866...87,563,776
Ensembl chr10:87,561,326...87,565,334
JBrowse link
G G6pd glucose-6-phosphate dehydrogenase decreases expression ISO Bortezomib results in decreased expression of G6PD mRNA CTD PMID:20977926 NCBI chr  X:152,201,081...152,220,863
Ensembl chr  X:152,201,098...152,220,801
JBrowse link
G Gabarapl1 GABA type A receptor associated protein like 1 increases expression ISO Bortezomib results in increased expression of GABARAPL1 mRNA CTD PMID:20977926 NCBI chr 4:162,980,309...162,989,452
Ensembl chr 4:162,980,249...162,989,450
JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha increases expression
multiple interactions
ISO
EXP
Bortezomib results in increased expression of GADD45A mRNA
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GADD45A mRNA
CTD PMID:20830808 PMID:20977926 PMID:25522274 NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
JBrowse link
G Gadd45b growth arrest and DNA-damage-inducible, beta increases expression
multiple interactions
ISO Bortezomib results in increased expression of GADD45B mRNA
Bortezomib inhibits the reaction [lipopolysaccharide A results in increased expression of GADD45B mRNA]
CTD PMID:15509775 PMID:15797874 PMID:17895889 PMID:17898295 NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046
JBrowse link
G Gadd45g growth arrest and DNA-damage-inducible, gamma increases expression ISO Bortezomib results in increased expression of GADD45G mRNA CTD PMID:17898295 NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610
JBrowse link
G Galnt4 polypeptide N-acetylgalactosaminyltransferase 4 increases expression ISO Bortezomib results in increased expression of GALNT4 mRNA CTD PMID:20977926 NCBI chr 7:33,925,229...33,927,770 JBrowse link
G Ganab glucosidase II alpha subunit decreases expression ISO Bortezomib results in decreased expression of GANAB mRNA CTD PMID:20977926 NCBI chr 1:205,793,810...205,813,701
Ensembl chr 1:205,793,895...205,813,695
JBrowse link
G Gas7 growth arrest specific 7 decreases expression ISO Bortezomib results in decreased expression of GAS7 mRNA CTD PMID:20977926 NCBI chr10:52,152,728...52,383,276
Ensembl chr10:52,152,493...52,383,276
JBrowse link
G Gbp2 guanylate binding protein 2 increases expression ISO Bortezomib results in increased expression of GBP2 mRNA CTD PMID:20977926 NCBI chr 2:231,332,488...231,348,573
Ensembl chr 2:231,332,284...231,348,571
JBrowse link
G Gcnt2 glucosaminyl (N-acetyl) transferase 2 (I blood group) increases expression ISO Bortezomib results in increased expression of GCNT2 mRNA CTD PMID:20977926 NCBI chr17:23,796,859...23,901,625
Ensembl chr17:23,796,859...23,901,611
JBrowse link
G Gdf15 growth differentiation factor 15 increases expression
multiple interactions
EXP
ISO
Bortezomib results in increased expression of GDF15 mRNA
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of GDF15 mRNA
CTD PMID:20830808 PMID:25522274 NCBI chr16:18,805,312...18,807,893
Ensembl chr16:18,805,239...18,808,055
JBrowse link
G Ghr growth hormone receptor increases expression ISO Bortezomib results in increased expression of GHR mRNA CTD PMID:17895889 NCBI chr 2:52,541,452...52,804,960
Ensembl chr 2:52,542,594...52,804,735
JBrowse link
G Git1 GIT ArfGAP 1 decreases expression ISO Bortezomib results in decreased expression of GIT1 mRNA CTD PMID:20977926 NCBI chr10:62,342,082...62,356,379
Ensembl chr10:62,342,299...62,356,373
JBrowse link
G Gkap1 G kinase anchoring protein 1 increases expression ISO Bortezomib results in increased expression of GKAP1 mRNA CTD PMID:20977926 NCBI chr17:6,383,963...6,423,684
Ensembl chr17:6,383,963...6,423,679
JBrowse link
G Gla galactosidase, alpha increases expression ISO Bortezomib results in increased expression of GLA mRNA CTD PMID:20977926 NCBI chr  X:97,769,227...97,780,646
Ensembl chr  X:97,768,996...97,780,664
JBrowse link
G Gnai3 G protein subunit alpha i3 increases expression ISO Bortezomib results in increased expression of GNAI3 mRNA CTD PMID:20977926 NCBI chr 2:195,742,765...195,780,720
Ensembl chr 2:195,742,642...195,780,742
JBrowse link
G Gosr2 golgi SNAP receptor complex member 2 increases expression ISO Bortezomib results in increased expression of GOSR2 mRNA CTD PMID:20977926 NCBI chr10:88,585,291...88,605,642
Ensembl chr10:88,586,299...88,605,625
JBrowse link
G Gpank1 G patch domain and ankyrin repeats 1 increases expression ISO Bortezomib results in increased expression of GPANK1 mRNA CTD PMID:20977926 NCBI chr20:3,697,641...3,700,814
Ensembl chr20:3,697,641...3,700,858
JBrowse link
G Gpat3 glycerol-3-phosphate acyltransferase 3 increases expression ISO Bortezomib results in increased expression of GPAT3 mRNA CTD PMID:20977926 NCBI chr14:8,715,367...8,768,051
Ensembl chr14:8,714,373...8,766,490
JBrowse link
G Gpatch2l G patch domain containing 2-like increases expression ISO Bortezomib results in increased expression of GPATCH2L mRNA CTD PMID:20977926 NCBI chr 6:105,883,383...105,935,644
Ensembl chr 6:105,883,460...105,934,888
JBrowse link
G Gphn gephyrin decreases expression ISO Bortezomib results in decreased expression of GPHN mRNA CTD PMID:20977926 NCBI chr 6:96,954,365...97,483,617
Ensembl chr 6:96,892,148...97,483,612
JBrowse link
G Gpr157 G protein-coupled receptor 157 decreases expression ISO Bortezomib results in decreased expression of GPR157 mRNA CTD PMID:20977926 NCBI chr 5:160,550,703...160,566,432
Ensembl chr 5:160,550,713...160,566,432
JBrowse link
G Gpsm3 G-protein signaling modulator 3 decreases expression ISO Bortezomib results in decreased expression of GPSM3 mRNA CTD PMID:20977926 NCBI chr20:4,157,123...4,158,984
Ensembl chr20:4,157,123...4,159,035
JBrowse link
G Gsk3a glycogen synthase kinase 3 alpha multiple interactions ISO [Bortezomib co-treated with lonafarnib] results in decreased expression of GSK3A protein modified form CTD PMID:16118318 NCBI chr 1:80,815,843...80,825,732
Ensembl chr 1:80,815,850...80,825,802
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions ISO [Bortezomib co-treated with lonafarnib] results in decreased expression of GSK3B protein modified form; Bortezomib results in decreased activity of and results in increased phosphorylation of GSK3B protein; GSK3B protein mutant form inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Wortmannin inhibits the reaction [Bortezomib results in decreased activity of and results in increased phosphorylation of GSK3B protein] CTD PMID:16118318 PMID:24085292 NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
JBrowse link
G Gspt1 G1 to S phase transition 1 decreases expression ISO Bortezomib results in decreased expression of GSPT1 mRNA CTD PMID:20977926 NCBI chr10:4,362,528...4,397,215
Ensembl chr10:4,362,510...4,397,198
JBrowse link
G Gsr glutathione-disulfide reductase increases expression ISO Bortezomib results in increased expression of GSR mRNA CTD PMID:20977926 NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
JBrowse link
G Gstcd glutathione S-transferase, C-terminal domain containing decreases expression ISO Bortezomib results in decreased expression of GSTCD mRNA CTD PMID:20977926 NCBI chr 2:221,499,083...221,591,888
Ensembl chr 2:221,499,083...221,591,857
JBrowse link
G Gstm4 glutathione S-transferase mu 4 decreases expression ISO Bortezomib results in decreased expression of GSTM4 mRNA CTD PMID:20977926 NCBI chr 2:195,667,940...195,685,315
Ensembl chr 2:195,680,004...195,685,323
JBrowse link
G Gtf3c2 general transcription factor IIIC subunit 2 decreases expression ISO Bortezomib results in decreased expression of GTF3C2 mRNA CTD PMID:20977926 NCBI chr 6:25,196,439...25,221,338
Ensembl chr 6:25,197,268...25,220,490
JBrowse link
G Gtpbp1 GTP binding protein 1 decreases expression ISO Bortezomib results in decreased expression of GTPBP1 mRNA CTD PMID:20977926 NCBI chr 7:111,248,254...111,272,705
Ensembl chr 7:111,248,254...111,272,705
JBrowse link
G Gzma granzyme A decreases expression ISO Bortezomib results in decreased expression of GZMA mRNA CTD PMID:20977926 NCBI chr 2:44,740,638...44,752,471
Ensembl chr 2:44,740,569...44,752,493
JBrowse link
G Gzmb granzyme B increases expression ISO Bortezomib results in increased expression of GZMB mRNA CTD PMID:20977926 NCBI chr15:30,343,361...30,346,792 JBrowse link
G H2ax H2A.X variant histone multiple interactions
decreases phosphorylation
increases expression
ISO
EXP
[Bortezomib co-treated with romidepsin] results in increased phosphorylation of H2AX protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with romidepsin] results in increased phosphorylation of H2AX protein]; leptomycin B promotes the reaction [Bortezomib results in increased expression of H2AX protein modified form]
Bortezomib results in decreased phosphorylation of H2AX protein
Bortezomib inhibits the reaction [Doxorubicin results in increased expression of H2AX protein]; Bortezomib inhibits the reaction [Etoposide results in increased expression of H2AX protein]
CTD PMID:15173094 PMID:16778179 PMID:17875725 PMID:18790767 PMID:32482060 NCBI chr 8:44,671,927...44,673,257
Ensembl chr 8:44,671,786...44,673,239
JBrowse link
G H6pd hexose-6-phosphate dehydrogenase (glucose 1-dehydrogenase) decreases expression ISO Bortezomib results in decreased expression of H6PD mRNA CTD PMID:20977926 NCBI chr 5:160,434,499...160,470,203
Ensembl chr 5:160,438,697...160,470,171
JBrowse link
G Hadha hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha increases expression ISO Bortezomib results in increased expression of HADHA mRNA CTD PMID:20977926 NCBI chr 6:26,187,969...26,227,605
Ensembl chr 6:26,187,956...26,227,869
JBrowse link
G Hdac10 histone deacetylase 10 decreases expression ISO Bortezomib results in decreased expression of HDAC10 mRNA CTD PMID:20977926 NCBI chr 7:120,199,126...120,205,850
Ensembl chr 7:120,199,129...120,204,228
JBrowse link
G Hdac4 histone deacetylase 4 decreases expression ISO Bortezomib results in decreased expression of HDAC4 mRNA CTD PMID:17659339 NCBI chr 9:92,503,467...92,750,164
Ensembl chr 9:92,507,611...92,750,164
JBrowse link
G Hdac6 histone deacetylase 6 decreases response to substance ISO HDAC6 results in decreased susceptibility to Bortezomib CTD PMID:16585204 NCBI chr  X:14,550,645...14,572,445
Ensembl chr  X:14,551,044...14,572,441
JBrowse link
G Hectd2 HECT domain E3 ubiquitin protein ligase 2 increases expression ISO Bortezomib results in increased expression of HECTD2 mRNA CTD PMID:20977926 NCBI chr 1:234,274,967...234,345,598
Ensembl chr 1:234,275,705...234,343,487
JBrowse link
G Hecw1 HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HECW1 mRNA CTD PMID:25522274 NCBI chr17:50,671,239...51,084,536
Ensembl chr17:50,670,954...51,080,720
JBrowse link
G Hexd hexosaminidase D decreases expression ISO Bortezomib results in decreased expression of HEXD mRNA CTD PMID:20977926 NCBI chr10:106,479,781...106,498,799
Ensembl chr10:106,480,194...106,498,799
JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha increases expression ISO Bortezomib results in increased expression of HIF1A protein CTD PMID:16061869 NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
JBrowse link
G Hikeshi heat shock protein nuclear import factor multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of HIKESHI mRNA CTD PMID:25522274 NCBI chr 1:143,825,922...143,849,374
Ensembl chr 1:143,825,923...143,849,363
JBrowse link
G Hist1h2ail1 histone cluster 1 H2a family member I like 1 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of H3C6 mRNA CTD PMID:25522274 NCBI chr17:41,568,666...41,569,076
Ensembl chr17:41,568,471...41,569,109
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
increases response to substance
increases expression
ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of HMOX1 mRNA; [cobaltiprotoporphyrin results in increased expression of HMOX1 protein] which results in increased susceptibility to Bortezomib; abexinostat promotes the reaction [Bortezomib results in increased expression of HMOX1 mRNA]
HMOX1 protein results in increased susceptibility to Bortezomib
Bortezomib results in increased expression of HMOX1 mRNA; Bortezomib results in increased expression of HMOX1 protein
CTD PMID:15509775 PMID:17895889 PMID:19417023 PMID:20471514 PMID:25913414 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
JBrowse link
G Hmox2 heme oxygenase 2 multiple interactions ISO abexinostat promotes the reaction [Bortezomib results in decreased expression of HMOX2 mRNA] CTD PMID:19417023 NCBI chr10:10,797,076...10,831,178
Ensembl chr10:10,797,055...10,831,148
JBrowse link
G Hnrnpll heterogeneous nuclear ribonucleoprotein L-like increases expression ISO Bortezomib results in increased expression of HNRNPLL mRNA CTD PMID:20977926 NCBI chr 6:14,969,953...15,000,574
Ensembl chr 6:14,970,057...14,999,745
JBrowse link
G Hoxa11 homeobox A11 decreases expression ISO Bortezomib results in decreased expression of HOXA11 mRNA CTD PMID:20977926 NCBI chr 4:81,342,527...81,346,189
Ensembl chr 4:81,342,528...81,346,232
JBrowse link
G Hps3 HPS3, biogenesis of lysosomal organelles complex 2 subunit 1 decreases expression ISO Bortezomib results in decreased expression of HPS3 mRNA CTD PMID:20977926 NCBI chr 2:102,484,574...102,527,580
Ensembl chr 2:102,484,574...102,526,047
JBrowse link
G Hras HRas proto-oncogene, GTPase multiple interactions ISO ATG5 gene mutant form inhibits the reaction [HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein]]; HRAS protein promotes the reaction [Bortezomib results in increased cleavage of and results in increased activity of CASP3 protein] CTD PMID:22842577 NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615
JBrowse link
G Hsf1 heat shock transcription factor 1 increases expression
increases activity
multiple interactions
ISO Bortezomib results in increased expression of HSF1 mRNA
Bortezomib results in increased activity of HSF1 protein
Bortezomib promotes the reaction [HSF1 protein binds to HSPA1A promoter]
CTD PMID:17895889 PMID:23874968 PMID:31540997 NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
JBrowse link
G Hsp90aa1 heat shock protein 90 alpha family class A member 1 increases expression
decreases expression
ISO
EXP
Bortezomib results in increased expression of HSP90AA1 mRNA
Bortezomib results in decreased expression of HSP90AA1 mRNA
CTD PMID:17895889 PMID:20471514 PMID:20830808 NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268
JBrowse link
G Hsp90ab1 heat shock protein 90 alpha family class B member 1 increases expression ISO Bortezomib results in increased expression of HSP90AB1 mRNA CTD PMID:17895889 NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488
JBrowse link
G Hspa1a heat shock protein family A (Hsp70) member 1A multiple interactions
decreases response to substance
increases expression
ISO Bortezomib promotes the reaction [HSF1 protein binds to HSPA1A promoter]
HSPA1A protein results in decreased susceptibility to Bortezomib
Bortezomib results in increased expression of HSPA1A mRNA
CTD PMID:17895889 PMID:23874968
G Hspa1b heat shock protein family A (Hsp70) member 1B increases expression
affects response to substance
decreases response to substance
ISO Bortezomib results in increased expression of HSPA1B mRNA
HSPA1B protein affects the susceptibility to Bortezomib
HSPA1B protein results in decreased susceptibility to Bortezomib
CTD PMID:15509775 PMID:17895889 PMID:23874968 NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240
JBrowse link
G Hspa4l heat shock protein family A (Hsp70) member 4 like increases expression EXP Bortezomib results in increased expression of HSPA4L mRNA CTD PMID:20830808 NCBI chr 2:123,740,384...123,793,088
Ensembl chr 2:123,740,384...123,793,084
JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 multiple interactions
increases expression
decreases response to substance
ISO Bortezomib inhibits the reaction [Brefeldin A results in increased expression of HSPA5 protein]; Bortezomib inhibits the reaction [Tunicamycin results in increased expression of HSPA5 protein]; Bortezomib promotes the reaction [gambogic acid results in increased expression of HSPA5 protein]; Bortezomib promotes the reaction [geldanamycin results in increased expression of HSPA5 protein]; gambogic acid promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; geldanamycin promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]
Bortezomib results in increased expression of HSPA5 mRNA
HSPA5 results in decreased susceptibility to Bortezomib
Bortezomib results in increased expression of HSPA5; Bortezomib results in increased expression of HSPA5 mRNA; Bortezomib results in increased expression of HSPA5 protein
CTD PMID:15141013 PMID:15509775 PMID:16024631 PMID:16357177 PMID:18641367 More... NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
JBrowse link
G Hspb1 heat shock protein family B (small) member 1 increases expression
decreases response to substance
EXP
ISO
Bortezomib results in increased expression of HSPB1 mRNA
HSPB1 protein results in decreased susceptibility to Bortezomib
CTD PMID:14559800 PMID:20830808 NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743
JBrowse link
G Hsph1 heat shock protein family H (Hsp110) member 1 increases expression ISO Bortezomib results in increased expression of HSPH1 mRNA CTD PMID:17898295 NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224
JBrowse link
G Htr2b 5-hydroxytryptamine receptor 2B decreases expression ISO Bortezomib results in decreased expression of HTR2B mRNA CTD PMID:20977926 NCBI chr 9:86,735,793...86,756,640
Ensembl chr 9:86,742,102...86,755,108
JBrowse link
G Htra2 HtrA serine peptidase 2 affects localization ISO Bortezomib affects the localization of HTRA2 protein CTD PMID:16024631 NCBI chr 4:115,556,914...115,560,202
Ensembl chr 4:115,556,916...115,560,095
JBrowse link
G Ibtk inhibitor of Bruton tyrosine kinase increases expression ISO Bortezomib results in increased expression of IBTK mRNA CTD PMID:20977926 NCBI chr 8:86,625,591...86,698,661
Ensembl chr 8:86,625,597...86,698,260
JBrowse link
G Icam1 intercellular adhesion molecule 1 multiple interactions
decreases expression
ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of ICAM1 mRNA; [romidepsin co-treated with Bortezomib] results in decreased expression of ICAM1 protein
Bortezomib results in decreased expression of ICAM1 mRNA
CTD PMID:18223231 PMID:20471514 PMID:25913414 NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
JBrowse link
G Ide insulin degrading enzyme increases expression ISO Bortezomib results in increased expression of IDE mRNA CTD PMID:20977926 NCBI chr 1:235,002,984...235,102,448
Ensembl chr 1:234,995,351...235,102,440
JBrowse link
G Idh3a isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha decreases expression ISO Bortezomib results in decreased expression of IDH3A mRNA CTD PMID:30818834 NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:54,971,740...54,991,084
JBrowse link
G Ifi44 interferon-induced protein 44 increases expression ISO Bortezomib results in increased expression of IFI44 mRNA CTD PMID:20977926 NCBI chr 2:240,626,058...240,643,879
Ensembl chr 2:240,626,066...240,643,844
JBrowse link
G Ifitm1 interferon induced transmembrane protein 1 decreases expression ISO Bortezomib results in decreased expression of IFITM1 mRNA CTD PMID:17659339 NCBI chr 1:196,067,163...196,069,169
Ensembl chr 1:196,067,963...196,069,169
JBrowse link
G Ifng interferon gamma multiple interactions ISO [Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]] CTD PMID:30482226 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
JBrowse link
G Ifrd2 interferon-related developmental regulator 2 decreases expression ISO Bortezomib results in decreased expression of IFRD2 mRNA CTD PMID:20977926 NCBI chr 8:108,260,969...108,266,191
Ensembl chr 8:108,260,969...108,266,194
JBrowse link
G Igf1r insulin-like growth factor 1 receptor increases response to substance ISO IGF1R gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr 1:121,549,839...121,838,545
Ensembl chr 1:121,550,743...121,831,777
JBrowse link
G Igf2 insulin-like growth factor 2 multiple interactions
decreases response to substance
ISO Bortezomib inhibits the reaction [IGF2 protein results in increased expression of STS mRNA]; Bortezomib inhibits the reaction [IGF2 protein results in increased expression of STS protein]
Bortezomib results in decreased susceptibility to IGF2 protein
CTD PMID:24055520 NCBI chr 1:197,814,409...197,831,802
Ensembl chr 1:197,814,410...197,823,018
JBrowse link
G Ikbkb inhibitor of nuclear factor kappa B kinase subunit beta multiple interactions
decreases expression
ISO Bortezomib promotes the reaction [abexinostat results in decreased expression of IKBKB mRNA]; IKBKB protein affects the reaction [Bortezomib results in increased phosphorylation of and results in increased degradation of NFKBIA protein]
Bortezomib results in decreased expression of IKBKB mRNA
CTD PMID:19417023 PMID:20471514 PMID:24085292 NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
JBrowse link
G Ikzf1 IKAROS family zinc finger 1 decreases expression ISO Bortezomib results in decreased expression of IKZF1 mRNA CTD PMID:20977926 NCBI chr14:86,255,065...86,340,839
Ensembl chr14:86,255,065...86,342,416
JBrowse link
G Il10 interleukin 10 affects expression ISO Bortezomib affects the expression of IL10 protein CTD PMID:19922463 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
JBrowse link
G Il15 interleukin 15 increases expression ISO Bortezomib results in increased expression of IL15 mRNA CTD PMID:20977926 NCBI chr19:25,640,013...25,706,818
Ensembl chr19:25,640,251...25,706,820
JBrowse link
G Il18r1 interleukin 18 receptor 1 increases expression ISO Bortezomib results in increased expression of IL18R1 mRNA CTD PMID:17895889 NCBI chr 9:42,727,416...42,760,971
Ensembl chr 9:42,727,869...42,760,715
JBrowse link
G Il1r1 interleukin 1 receptor type 1 increases expression ISO Bortezomib results in increased expression of IL1R1 mRNA CTD PMID:17895889 NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937
JBrowse link
G Il23a interleukin 23 subunit alpha increases expression ISO Bortezomib results in increased expression of IL23A mRNA CTD PMID:17895889 NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923
JBrowse link
G Il6 interleukin 6 multiple interactions
increases expression
decreases expression
decreases secretion
ISO [Dexamethasone co-treated with Bortezomib] inhibits the reaction [IL6 protein results in increased expression of SOD2 mRNA]; [Dexamethasone co-treated with Bortezomib] results in decreased expression of IL6 mRNA; [Dexamethasone co-treated with Bortezomib] results in decreased secretion of IL6 protein; Bortezomib inhibits the reaction [IL6 protein results in decreased susceptibility to Dexamethasone]
Bortezomib inhibits the reaction [[Chloroquine co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL6 protein]; Bortezomib inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL6 protein]
Bortezomib results in increased expression of IL6 mRNA
Bortezomib results in decreased expression of IL6 mRNA
Bortezomib results in decreased secretion of IL6 protein
CTD PMID:17895889 PMID:23063726 PMID:28134560 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
JBrowse link
G Il7r interleukin 7 receptor increases expression
multiple interactions
ISO Bortezomib results in increased expression of IL7R mRNA
[BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased expression of IL7R mRNA
CTD PMID:20471514 PMID:25522274 NCBI chr 2:58,452,393...58,477,757
Ensembl chr 2:58,454,217...58,477,757
JBrowse link
G Ino80b INO80 complex subunit B decreases expression ISO Bortezomib results in decreased expression of INO80B mRNA CTD PMID:20977926 NCBI chr 4:115,627,907...115,631,069
Ensembl chr 4:115,627,908...115,631,456
JBrowse link
G Irak1 interleukin-1 receptor-associated kinase 1 decreases expression ISO Bortezomib results in decreased expression of IRAK1 mRNA CTD PMID:20471514 NCBI chr  X:151,768,621...151,778,521
Ensembl chr  X:151,768,777...151,778,521
JBrowse link
G Irak2 interleukin-1 receptor-associated kinase 2 increases expression ISO Bortezomib results in increased expression of IRAK2 mRNA CTD PMID:20977926 NCBI chr 4:146,786,004...146,842,615
Ensembl chr 4:146,786,100...146,842,602
JBrowse link
G Irs1 insulin receptor substrate 1 decreases degradation ISO Bortezomib results in decreased degradation of IRS1 protein CTD PMID:16227402 NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
JBrowse link
G Isca1 iron-sulfur cluster assembly 1 increases expression ISO Bortezomib results in increased expression of ISCA1 mRNA CTD PMID:20977926 NCBI chr17:4,905,291...4,917,955
Ensembl chr17:4,905,287...4,917,955
JBrowse link
G Itga6 integrin subunit alpha 6 decreases expression ISO Bortezomib results in decreased expression of ITGA6 mRNA CTD PMID:20977926 NCBI chr 3:56,604,512...56,689,428
Ensembl chr 3:56,617,268...56,689,428
JBrowse link
G Itgal integrin subunit alpha L decreases expression ISO Bortezomib results in decreased expression of ITGAL mRNA CTD PMID:20977926 NCBI chr 1:181,918,183...181,955,735
Ensembl chr 1:181,918,183...181,955,732
JBrowse link
G Itgav integrin subunit alpha V multiple interactions
increases expression
ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of ITGAV mRNA
Bortezomib results in increased expression of ITGAV mRNA
CTD PMID:20471514 PMID:25913414 NCBI chr 3:68,838,524...68,926,653
Ensembl chr 3:68,838,189...68,926,639
JBrowse link
G Itgb6 integrin subunit beta 6 increases expression ISO Bortezomib results in increased expression of ITGB6 mRNA CTD PMID:20977926 NCBI chr 3:45,046,295...45,170,532
Ensembl chr 3:45,048,044...45,121,671
JBrowse link
G Jak1 Janus kinase 1 decreases expression ISO Bortezomib results in decreased expression of JAK1 mRNA CTD PMID:20977926 NCBI chr 5:115,780,248...115,888,841
Ensembl chr 5:115,780,248...115,888,926
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit decreases expression
increases expression
increases phosphorylation
multiple interactions
ISO
EXP
Bortezomib results in decreased expression of JUN mRNA
Bortezomib results in increased expression of JUN mRNA; Bortezomib results in increased expression of JUN protein
Bortezomib results in increased expression of JUN mRNA; Bortezomib results in increased expression of JUN protein; Bortezomib results in increased expression of JUN protein modified form
Bortezomib results in increased phosphorylation of JUN protein
[arsenic trioxide co-treated with Bortezomib] results in decreased expression of JUN mRNA; [arsenic trioxide co-treated with Bortezomib] results in increased activity of JUN protein modified form; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of JUN protein; pyrazolanthrone inhibits the reaction [Bortezomib results in increased phosphorylation of JUN protein]
CTD PMID:12393500 PMID:16357177 PMID:16985072 PMID:17351739 PMID:17495969 More... NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
JBrowse link
G Jund JunD proto-oncogene, AP-1 transcription factor subunit decreases expression ISO Bortezomib results in decreased expression of JUND mRNA CTD PMID:20977926 NCBI chr16:18,734,121...18,735,799
Ensembl chr16:18,734,122...18,735,799
JBrowse link
G Kat2b lysine acetyltransferase 2B decreases expression ISO Bortezomib results in decreased expression of KAT2B mRNA CTD PMID:20471514 NCBI chr 9:6,562,525...6,667,064 JBrowse link
G Kat6b lysine acetyltransferase 6B decreases expression ISO Bortezomib results in decreased expression of KAT6B mRNA CTD PMID:20977926 NCBI chr15:2,638,885...2,811,977
Ensembl chr15:2,639,200...2,812,316
JBrowse link
G Katnal1 katanin catalytic subunit A1 like 1 increases expression ISO Bortezomib results in increased expression of KATNAL1 mRNA CTD PMID:20977926 NCBI chr12:6,094,663...6,156,114
Ensembl chr12:6,102,836...6,157,553
JBrowse link
G Kcmf1 potassium channel modulatory factor 1 increases expression ISO Bortezomib results in increased expression of KCMF1 mRNA CTD PMID:20977926 NCBI chr 4:104,888,452...104,950,234
Ensembl chr 4:104,889,847...104,950,234
JBrowse link
G Kctd10 potassium channel tetramerization domain containing 10 increases expression ISO Bortezomib results in increased expression of KCTD10 mRNA CTD PMID:20977926 NCBI chr12:42,230,159...42,248,792
Ensembl chr12:42,230,269...42,248,783
JBrowse link
G Kdelr1 KDEL endoplasmic reticulum protein retention receptor 1 decreases expression ISO Bortezomib results in decreased expression of KDELR1 mRNA CTD PMID:20977926 NCBI chr 1:96,347,258...96,358,145
Ensembl chr 1:96,347,150...96,358,157
JBrowse link
G Kdm4b lysine demethylase 4B decreases expression ISO Bortezomib results in decreased expression of KDM4B mRNA CTD PMID:20977926 NCBI chr 9:1,158,737...1,237,228
Ensembl chr 9:1,158,752...1,236,543
JBrowse link
G Kdm5c lysine demethylase 5C decreases expression ISO Bortezomib results in decreased expression of KDM5C mRNA CTD PMID:20977926 NCBI chr  X:21,345,459...21,387,045
Ensembl chr  X:21,345,481...21,381,870
JBrowse link
G Kdr kinase insert domain receptor multiple interactions ISO [Bortezomib co-treated with sorafenib] results in decreased phosphorylation of KDR protein CTD PMID:16985072 NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
JBrowse link
G Kif22 kinesin family member 22 decreases expression ISO Bortezomib results in decreased expression of KIF22 mRNA CTD PMID:20977926 NCBI chr 1:181,635,347...181,650,351
Ensembl chr 1:181,635,183...181,650,401
JBrowse link
G Kif9 kinesin family member 9 decreases expression ISO Bortezomib results in decreased expression of KIF9 mRNA CTD PMID:20977926 NCBI chr 8:110,459,467...110,504,492
Ensembl chr 8:110,459,383...110,505,252
JBrowse link
G Kifc1 kinesin family member C1 decreases expression ISO Bortezomib results in decreased expression of KIFC1 mRNA CTD PMID:20977926 NCBI chr20:4,998,832...5,017,107
Ensembl chr20:4,999,047...5,017,105
JBrowse link
G Klf6 Kruppel-like factor 6 increases expression ISO Bortezomib results in increased expression of KLF6 mRNA CTD PMID:20977926 NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570
JBrowse link
G Klhdc7b kelch domain containing 7B increases expression ISO Bortezomib results in increased expression of KLHDC7B mRNA CTD PMID:20977926 NCBI chr 7:120,452,081...120,456,094
Ensembl chr 7:120,453,932...120,455,737
JBrowse link
G Klhl20 kelch-like family member 20 increases expression ISO Bortezomib results in increased expression of KLHL20 mRNA CTD PMID:20977926 NCBI chr13:73,363,451...73,408,346
Ensembl chr13:73,363,455...73,408,337
JBrowse link
G Klrk1 killer cell lectin like receptor K1 decreases expression ISO Bortezomib results in decreased expression of KLRK1 mRNA CTD PMID:20977926 NCBI chr 4:163,079,887...163,092,434
Ensembl chr 4:163,081,927...163,092,459
JBrowse link
G Kmt2a lysine methyltransferase 2A multiple interactions ISO [arsenic trioxide co-treated with Bortezomib] results in decreased expression of KMT2A mRNA CTD PMID:25913414 NCBI chr 8:45,116,771...45,193,320
Ensembl chr 8:45,118,814...45,193,181
JBrowse link
G Kpna2 karyopherin subunit alpha 2 increases expression ISO Bortezomib results in increased expression of KPNA2 mRNA CTD PMID:20977926 NCBI chr10:91,933,951...91,946,115
Ensembl chr10:91,933,951...91,946,150
JBrowse link
G Kri1 KRI1 homolog increases expression ISO Bortezomib results in increased expression of KRI1 mRNA CTD PMID:20977926 NCBI chr 8:19,817,015...19,831,516
Ensembl chr 8:19,817,017...19,831,392
JBrowse link
G Krit1 KRIT1, ankyrin repeat containing increases expression ISO Bortezomib results in increased expression of KRIT1 mRNA CTD PMID:20977926 NCBI chr 4:30,299,203...30,333,366
Ensembl chr 4:30,299,203...30,333,359
JBrowse link
G Ktn1 kinectin 1 increases expression ISO Bortezomib results in increased expression of KTN1 mRNA CTD PMID:20977926 NCBI chr15:20,913,665...21,002,588
Ensembl chr15:20,914,642...21,002,578
JBrowse link
G Lgals2 galectin 2 decreases expression ISO Bortezomib results in decreased expression of LGALS2 mRNA CTD PMID:17659339 NCBI chr 7:110,403,171...110,410,046
Ensembl chr 7:110,403,173...110,404,802
JBrowse link
G Lgals8 galectin 8 increases expression ISO Bortezomib results in increased expression of LGALS8 mRNA CTD PMID:20977926 NCBI chr17:58,024,652...58,052,764
Ensembl chr17:58,028,105...58,052,764
JBrowse link
G Lgr4 leucine-rich repeat-containing G protein-coupled receptor 4 multiple interactions ISO [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in decreased expression of LGR4 mRNA CTD PMID:25522274 NCBI chr 3:96,447,385...96,550,006
Ensembl chr 3:96,447,858...96,548,899
JBrowse link
G Lig4 DNA ligase 4 increases expression ISO Bortezomib results in increased expression of LIG4 mRNA CTD PMID:20977926 NCBI chr16:79,518,393...79,526,956
Ensembl chr16:79,518,312...79,527,040
JBrowse link
G Lima1 LIM domain and actin binding 1 increases expression ISO Bortezomib results in increased expression of LIMA1 mRNA CTD PMID:20977926 NCBI chr 7:130,901,717...131,001,573
Ensembl chr 7:130,901,717...131,001,473
JBrowse link
G Limd1 LIM domain containing 1 increases expression ISO Bortezomib results in increased expression of LIMD1 mRNA CTD PMID:20977926 NCBI chr 8:123,121,363...123,168,476
Ensembl chr 8:123,122,460...123,167,714
JBrowse link
G Lims1 LIM zinc finger domain containing 1 increases expression ISO Bortezomib results in increased expression of LIMS1 mRNA CTD PMID:20977926 NCBI chr20:26,309,833...26,418,511
Ensembl chr20:26,309,895...26,418,500
JBrowse link
G Lmna lamin A/C increases cleavage ISO Bortezomib results in increased cleavage of LMNA protein CTD PMID:20110775 NCBI chr 2:173,939,751...173,960,423
Ensembl chr 2:173,939,751...173,960,423
JBrowse link
G LOC100909954 uncharacterized LOC100909954 decreases expression ISO Bortezomib results in decreased expression of C14ORF132 mRNA CTD PMID:20977926 NCBI chr 6:124,365,466...124,398,449 JBrowse link
G LOC100911664 uncharacterized LOC100911664 increases expression ISO Bortezomib results in increased expression of C6ORF62 mRNA CTD PMID:20977926 NCBI chr17:40,256,211...40,267,851
Ensembl chr17:40,256,211...40,276,020
JBrowse link
G LOC361985 similar to NICE-3 decreases expression ISO Bortezomib results in decreased expression of C1ORF43 mRNA CTD PMID:20977926 NCBI chr 2:175,494,355...175,507,276
Ensembl chr 2:175,494,304...175,510,663
JBrowse link
G LOC686035 similar to heat shock 70kDa protein 6 (HSP70B) increases expression ISO Bortezomib results in increased expression of HSPA6 mRNA CTD PMID:15509775 PMID:17898295 PMID:20977926 NCBI chr13:83,271,340...83,275,267 JBrowse link
G LOC691807 hypothetical protein LOC691807 decreases expression ISO Bortezomib results in decreased expression of C4ORF3 mRNA CTD PMID:20977926 NCBI chr 2:211,055,925...211,057,685
Ensembl chr 2:211,055,911...211,057,681
JBrowse link
G Lrfn4 leucine rich repeat and fibronectin type III domain containing 4 decreases expression ISO Bortezomib results in decreased expression of LRFN4 mRNA CTD PMID:20977926 NCBI chr 1:201,888,569...201,891,861
Ensembl chr 1:201,888,569...201,891,861
JBrowse link
G Lrrc41 leucine rich repeat containing 41 decreases expression ISO Bortezomib results in decreased expression of LRRC41 mRNA CTD PMID:20977926 NCBI chr 5:129,554,547...129,575,450
Ensembl chr 5:129,554,547...129,575,449
JBrowse link
G Lrrfip1 LRR binding FLII interacting protein 1 increases expression ISO Bortezomib results in increased expression of LRRFIP1 mRNA CTD PMID:20977926 NCBI chr 9:91,592,032...91,720,250
Ensembl chr 9:91,643,197...91,720,250
JBrowse link
G Lsm4 LSM4 homolog, U6 small nuclear RNA and mRNA degradation associated decreases expression ISO Bortezomib results in decreased expression of LSM4 mRNA CTD PMID:20977926 NCBI chr16:18,755,481...18,761,106
Ensembl chr16:18,755,484...18,760,926
JBrowse link
G Lst1 leukocyte specific transcript 1 decreases expression ISO Bortezomib results in decreased expression of LST1 mRNA CTD PMID:20977926 NCBI chr20:3,634,680...3,639,731
Ensembl chr20:3,634,749...3,637,997
JBrowse link
G Luc7l LUC7-like increases expression ISO Bortezomib results in increased expression of LUC7L mRNA CTD PMID:20977926 NCBI chr10:15,273,340...15,307,131
Ensembl chr10:15,273,348...15,303,112
JBrowse link
G Ly96 lymphocyte antigen 96 multiple interactions ISO [arsenic trioxide co-treated with Bortezomib] results in increased expression of LY96 mRNA CTD PMID:25913414 NCBI chr 5:2,582,233...2,612,357
Ensembl chr 5:2,582,254...2,612,386
JBrowse link
G Lyn LYN proto-oncogene, Src family tyrosine kinase multiple interactions ISO [alvocidib co-treated with Bortezomib co-treated with ABL1 protein] results in decreased phosphorylation of LYN protein CTD PMID:15039284 NCBI chr 5:16,639,512...16,755,501
Ensembl chr 5:16,639,466...16,756,868
JBrowse link
G Maf1 MAF1 homolog, negative regulator of RNA polymerase III multiple interactions ISO Bortezomib inhibits the reaction [Cycloheximide results in increased degradation of MAF1 protein] CTD PMID:31645432 NCBI chr 7:108,075,173...108,078,252
Ensembl chr 7:108,075,189...108,078,249
JBrowse link
G Mafg MAF bZIP transcription factor G increases expression ISO Bortezomib results in increased expression of MAFG mRNA CTD PMID:20977926 NCBI chr10:105,903,307...105,911,845
Ensembl chr10:105,903,237...105,912,026
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO MAP1LC3B protein affects the reaction [Bortezomib results in increased phosphorylation of NFKBIA protein] CTD PMID:24085292 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 multiple interactions ISO [Bortezomib co-treated with Butyrates] results in decreased expression of MAP2K1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAP2K1 protein CTD PMID:12893773 NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
JBrowse link
G Map2k2 mitogen activated protein kinase kinase 2 decreases expression ISO Bortezomib results in decreased expression of MAP2K2 mRNA CTD PMID:20977926 NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243
JBrowse link
G Map2k4 mitogen activated protein kinase kinase 4 multiple interactions ISO alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAP2K4 protein]; Bortezomib results in increased phosphorylation of and results in increased activity of MAP2K4 protein CTD PMID:15039284 NCBI chr10:50,343,227...50,447,956
Ensembl chr10:50,344,915...50,447,993
JBrowse link
G Map2k6 mitogen-activated protein kinase kinase 6 decreases expression ISO Bortezomib results in decreased expression of MAP2K6 mRNA CTD PMID:20977926 NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293
JBrowse link
G Map4k3 mitogen-activated protein kinase kinase kinase kinase 3 increases expression ISO Bortezomib results in increased expression of MAP4K3 mRNA CTD PMID:20977926 NCBI chr 6:14,276,623...14,446,321
Ensembl chr 6:14,277,121...14,446,334
JBrowse link
G Map4k4 mitogen-activated protein kinase kinase kinase kinase 4 increases expression ISO Bortezomib results in increased expression of MAP4K4 mRNA CTD PMID:20977926 NCBI chr 9:42,200,708...42,326,708
Ensembl chr 9:42,200,278...42,326,698
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases expression
increases phosphorylation
decreases activity
ISO [Bortezomib co-treated with Butyrates] results in decreased expression of MAPK1 protein; [Bortezomib co-treated with panobinostat] results in decreased activity of MAPK1 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAPK1 protein; alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK1 protein modified form]; Bortezomib promotes the reaction [Curcumin results in decreased phosphorylation of MAPK1 protein]; lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK1 protein]
Bortezomib results in decreased activity of MAPK1 protein
CTD PMID:12893773 PMID:15039284 PMID:18445700 PMID:19383353 PMID:20701607 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
JBrowse link
G Mapk10 mitogen activated protein kinase 10 multiple interactions ISO [[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK10 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK10 protein; [Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK10 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK10 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK10 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK10 protein] CTD PMID:15173093 NCBI chr14:6,497,662...6,790,109
Ensembl chr14:6,497,707...6,786,201
JBrowse link
G Mapk14 mitogen activated protein kinase 14 multiple interactions ISO [Bortezomib co-treated with Butyrates] results in increased phosphorylation of MAPK14 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of MAPK14 protein; MAPK14 mutant form inhibits the reaction [Bortezomib results in increased cleavage of CASP3 protein] CTD PMID:12893773 PMID:18790767 NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases expression
increases phosphorylation
decreases activity
ISO [Bortezomib co-treated with Butyrates] results in decreased expression of MAPK3 protein; [Bortezomib co-treated with panobinostat] results in decreased activity of MAPK3 protein; [Bortezomib co-treated with vorinostat] results in decreased expression of MAPK3 protein; alvocidib inhibits the reaction [Bortezomib results in increased expression of MAPK3 protein modified form]; Bortezomib promotes the reaction [Curcumin results in decreased phosphorylation of MAPK3 protein]; lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK3 protein]
Bortezomib results in decreased activity of MAPK3 protein
CTD PMID:12893773 PMID:15039284 PMID:18445700 PMID:19383353 PMID:20701607 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions
increases phosphorylation
ISO [[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK8 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in increased phosphorylation of and results in increased activity of MAPK8 protein; [Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK8 protein; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of MAPK8 protein; [Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK8 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in increased phosphorylation of and results in increased activity of MAPK8 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in increased phosphorylation of and results in increased activity of MAPK8 protein]; alvocidib promotes the reaction [Bortezomib results in increased phosphorylation of and results in increased activity of MAPK8 protein]; Bortezomib results in increased phosphorylation of and results in increased activity of MAPK8 protein; CGC 11093 promotes the reaction [Bortezomib results in increased phosphorylation of MAPK8 protein]; MAPK8 results in increased susceptibility to [Bortezomib co-treated with CGC 11093] CTD PMID:12893773 PMID:15039284 PMID:15173093 PMID:16985072 PMID:18559525 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
JBrowse link
G Mapk9 mitogen-activated protein kinase 9 increases phosphorylation
multiple interactions
ISO Bortezomib results in increased phosphorylation of MAPK9 protein
[Bortezomib co-treated with arsenic trioxide] affects the expression of MAPK9 protein; [Bortezomib co-treated with sorafenib] results in increased phosphorylation of MAPK9 protein; CGC 11093 promotes the reaction [Bortezomib results in increased phosphorylation of MAPK9 protein]; MAPK9 results in increased susceptibility to [Bortezomib co-treated with CGC 11093]
CTD PMID:16985072 PMID:18559525 PMID:18718063 NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
JBrowse link
G Mapkap1 MAPK associated protein 1 decreases expression ISO Bortezomib results in decreased expression of MAPKAP1 mRNA CTD PMID:20977926 NCBI chr 3:17,715,813...17,918,387
Ensembl chr 3:17,715,834...17,918,384
JBrowse link
G Mapkapk2 MAPK activated protein kinase 2 decreases expression ISO Bortezomib results in decreased expression of MAPKAPK2 mRNA CTD PMID:20977926 NCBI chr13:42,513,762...42,560,061
Ensembl chr13:42,513,762...42,560,457
JBrowse link
G Mark2 microtubule affinity regulating kinase 2 decreases expression ISO Bortezomib results in decreased expression of MARK2 mRNA CTD PMID:20977926 NCBI chr 1:204,461,029...204,526,247
Ensembl chr 1:204,461,030...204,525,652
JBrowse link
G Maz MYC associated zinc finger protein decreases expression ISO Bortezomib results in decreased expression of MAZ mRNA CTD PMID:20977926 NCBI chr 1:181,629,742...181,635,193
Ensembl chr 1:181,629,729...181,650,408
JBrowse link
G Mbd1 methyl-CpG binding domain protein 1 decreases expression ISO Bortezomib results in decreased expression of MBD1 mRNA CTD PMID:20977926 NCBI chr18:67,869,870...67,884,501
Ensembl chr18:67,869,992...67,886,554
JBrowse link
G Mbd4 methyl-CpG binding domain 4 DNA glycosylase increases expression ISO Bortezomib results in increased expression of MBD4 mRNA CTD PMID:20977926 NCBI chr 4:148,893,049...148,904,833
Ensembl chr 4:148,894,280...148,904,982
JBrowse link
G Mbl2 mannose binding lectin 2 increases response to substance ISO MBL2 gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr 1:228,016,439...228,024,736 JBrowse link
G Mbnl1 muscleblind-like splicing regulator 1 decreases expression ISO Bortezomib results in decreased expression of MBNL1 mRNA CTD PMID:20977926 NCBI chr 2:144,639,819...144,814,395
Ensembl chr 2:144,670,285...144,814,368
JBrowse link
G Mbp myelin basic protein decreases expression ISO Bortezomib results in decreased expression of MBP mRNA CTD PMID:20977926 NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member multiple interactions
increases expression
decreases response to substance
increases cleavage
ISO [[Bortezomib co-treated with Butyrates] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of MCL1 protein; [[Bortezomib co-treated with vorinostat] results in increased abundance of Reactive Oxygen Species] which results in decreased expression of MCL1 protein; [Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in decreased expression of MCL1 protein; [Bortezomib co-treated with SCIO-469] results in decreased expression of MCL1 protein; [Bortezomib co-treated with SCIO-469] results in decreased expression of MCL1 protein modified form; [Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein]; Acetylcysteine inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with Butyrates] results in decreased expression of MCL1 protein]; Boc-D-FMK inhibits the reaction [[Bortezomib co-treated with vorinostat] results in decreased expression of MCL1 protein]; romidepsin inhibits the reaction [Bortezomib results in increased expression of MCL1 protein]; SCIO-469 promotes the reaction [Bortezomib results in increased cleavage of MCL1 protein]; TNFSF10 protein inhibits the reaction [Bortezomib results in increased expression of MCL1 protein]
Bortezomib inhibits the reaction [Acetaminophen results in decreased expression of MCL1 protein]
MCL1 protein results in decreased susceptibility to Bortezomib; MCL1 results in decreased susceptibility to Bortezomib
Bortezomib results in increased expression of MCL1; Bortezomib results in increased expression of MCL1 protein
CTD PMID:12893773 PMID:15173093 PMID:16617327 PMID:18223231 PMID:18534018 More... NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
JBrowse link
G Mcm7 minichromosome maintenance complex component 7 decreases expression ISO Bortezomib results in decreased expression of MCM7 mRNA CTD PMID:17659339 NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063
JBrowse link
G Mdc1 mediator of DNA damage checkpoint 1 decreases expression ISO Bortezomib results in decreased expression of MDC1 mRNA CTD PMID:20977926 NCBI chr20:2,893,693...2,912,394
Ensembl chr20:2,895,505...2,910,240
JBrowse link
G Mdm2 MDM2 proto-oncogene multiple interactions
increases cleavage
affects expression
ISO [CASP8 protein results in increased activity of CASP3 protein] affects the reaction [Bortezomib results in increased cleavage of MDM2 protein]; Bortezomib promotes the reaction [TP53 protein binds to MDM2 protein]
Bortezomib affects the expression of MDM2 protein
CTD PMID:12393500 NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
JBrowse link
G Me1 malic enzyme 1 increases expression ISO Bortezomib results in increased expression of ME1 mRNA CTD PMID:20977926 NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304
JBrowse link
G Mettl21a methyltransferase like 21A increases expression ISO Bortezomib results in increased expression of METTL21A mRNA CTD PMID:20977926 NCBI chr 9:65,934,253...65,999,964
Ensembl chr 9:65,978,051...65,987,550
JBrowse link
G Mettl27 methyltransferase like 27 decreases expression ISO Bortezomib results in decreased expression of METTL27 mRNA CTD PMID:20977926 NCBI chr12:21,757,545...21,766,698
Ensembl chr12:21,757,329...21,766,685
JBrowse link
G Mex3d mex-3 RNA binding family member D decreases expression ISO Bortezomib results in decreased expression of MEX3D mRNA CTD PMID:20977926 NCBI chr 7:9,325,575...9,332,705
Ensembl chr 7:9,325,488...9,332,096
JBrowse link
G Mfn1 mitofusin 1 decreases expression ISO Bortezomib results in decreased expression of MFN1 mRNA CTD PMID:20977926 NCBI chr 2:115,313,380...115,359,651
Ensembl chr 2:115,313,401...115,359,640
JBrowse link
G Mfng MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase decreases expression ISO Bortezomib results in decreased expression of MFNG mRNA CTD PMID:20977926 NCBI chr 7:110,310,810...110,328,653
Ensembl chr 7:110,310,812...110,328,653
JBrowse link
G Mgmt O-6-methylguanine-DNA methyltransferase multiple interactions ISO Bortezomib inhibits the reaction [Disulfiram results in increased degradation of MGMT protein] CTD PMID:24193513 NCBI chr 1:191,710,980...191,937,760
Ensembl chr 1:191,710,930...191,937,756
JBrowse link
G Mir21 microRNA 21 increases expression ISO Bortezomib results in increased expression of MIR21 mRNA CTD PMID:20977926 NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348
JBrowse link
G Mki67 marker of proliferation Ki-67 decreases expression
multiple interactions
ISO Bortezomib results in decreased expression of MKI67 protein
[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]]
CTD PMID:19372569 PMID:30482226 NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
JBrowse link
G Mllt11 MLLT11, transcription factor 7 cofactor increases expression ISO Bortezomib results in increased expression of MLLT11 mRNA CTD PMID:20977926 NCBI chr 2:182,795,790...182,804,960
Ensembl chr 2:182,795,790...182,797,199
JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions ISO Bortezomib promotes the reaction [butein results in decreased expression of MMP9 protein] CTD PMID:20696233 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
JBrowse link
G Mob3a MOB kinase activator 3A decreases expression ISO Bortezomib results in decreased expression of MOB3A mRNA CTD PMID:17659339 NCBI chr 7:9,010,490...9,027,888
Ensembl chr 7:9,010,587...9,027,879
JBrowse link
G Morc2 MORC family CW-type zinc finger 2 increases expression ISO Bortezomib results in increased expression of MORC2 mRNA CTD PMID:20977926 NCBI chr14:78,529,603...78,571,375
Ensembl chr14:78,527,009...78,571,343
JBrowse link
G Mpz myelin protein zero decreases expression EXP
ISO
Bortezomib results in decreased expression of MPZ mRNA; Bortezomib results in decreased expression of MPZ protein CTD PMID:20830808 NCBI chr13:83,570,811...83,576,680
Ensembl chr13:83,570,811...83,576,679
JBrowse link
G Mrpl19 mitochondrial ribosomal protein L19 increases expression ISO Bortezomib results in increased expression of MRPL19 mRNA CTD PMID:20977926 NCBI chr 4:114,521,824...114,526,053
Ensembl chr 4:114,521,824...114,526,053
JBrowse link
G Mrpl30 mitochondrial ribosomal protein L30 decreases expression ISO Bortezomib results in decreased expression of MRPL30 mRNA CTD PMID:20977926 NCBI chr 9:40,125,352...40,136,189
Ensembl chr 9:40,125,430...40,137,257
JBrowse link
G Mrps12 mitochondrial ribosomal protein S12 decreases expression ISO Bortezomib results in decreased expression of MRPS12 mRNA CTD PMID:20977926 NCBI chr 1:84,025,896...84,028,896
Ensembl chr 1:84,025,899...84,028,780
JBrowse link
G Mrps5 mitochondrial ribosomal protein S5 decreases expression ISO Bortezomib results in decreased expression of MRPS5 mRNA CTD PMID:20977926 NCBI chr 3:114,821,046...114,837,291
Ensembl chr 3:114,821,046...114,837,291
JBrowse link
G Msh6 mutS homolog 6 decreases expression ISO Bortezomib results in decreased expression of MSH6 mRNA CTD PMID:17659339 NCBI chr 6:6,562,631...6,579,995
Ensembl chr 6:6,562,632...6,579,956
JBrowse link
G Mtmr6 myotubularin related protein 6 increases expression ISO Bortezomib results in increased expression of MTMR6 mRNA CTD PMID:20977926 NCBI chr15:34,419,868...34,457,863
Ensembl chr15:34,419,903...34,457,861
JBrowse link
G Muc1 mucin 1, cell surface associated decreases expression ISO Bortezomib results in decreased expression of MUC1 mRNA CTD PMID:20977926 NCBI chr 2:174,635,559...174,640,738
Ensembl chr 2:174,635,995...174,640,733
JBrowse link
G Mutyh mutY DNA glycosylase decreases expression ISO Bortezomib results in decreased expression of MUTYH mRNA CTD PMID:17659339 NCBI chr 5:130,274,034...130,286,149
Ensembl chr 5:130,274,122...130,286,146
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor multiple interactions
increases expression
decreases expression
ISO [Bortezomib co-treated with abexinostat] results in decreased expression of MYC mRNA; Bortezomib promotes the reaction [abexinostat results in decreased expression of MYC protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of HSPA5 protein]; MYC protein promotes the reaction [Bortezomib results in increased expression of PMAIP1 protein]
Bortezomib results in increased expression of MYC protein
Bortezomib results in decreased expression of MYC protein
CTD PMID:12902978 PMID:18641367 PMID:19417023 PMID:20022965 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
JBrowse link
G Myd88 MYD88, innate immune signal transduction adaptor decreases expression ISO Bortezomib results in decreased expression of MYD88 mRNA CTD PMID:20471514 NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
JBrowse link
G Myl12a myosin light chain 12A increases expression ISO Bortezomib results in increased expression of MYL12A mRNA CTD PMID:20977926 NCBI chr 9:110,891,970...110,899,655
Ensembl chr 9:110,873,959...110,916,580
JBrowse link
G Myo5a myosin VA increases response to substance ISO MYO5A gene SNP results in increased susceptibility to Bortezomib CTD PMID:20864405 NCBI chr 8:75,811,985...75,980,049
Ensembl chr 8:75,812,412...75,975,918
JBrowse link
G Naa80 N(alpha)-acetyltransferase 80, NatH catalytic subunit decreases expression ISO Bortezomib results in decreased expression of NAA80 mRNA CTD PMID:17659339 NCBI chr 8:108,254,314...108,257,564
Ensembl chr 8:108,253,302...108,257,563
JBrowse link
G Nab2 Ngfi-A binding protein 2 decreases expression ISO Bortezomib results in decreased expression of NAB2 mRNA CTD PMID:20977926 NCBI chr 7:63,497,589...63,504,105
Ensembl chr 7:63,497,589...63,503,989
JBrowse link
G Nabp1 nucleic acid binding protein 1 increases expression ISO Bortezomib results in increased expression of NABP1 mRNA CTD PMID:20977926 NCBI chr 9:50,098,552...50,133,982
Ensembl chr 9:50,126,726...50,134,107
JBrowse link
G Nadk NAD kinase decreases expression ISO Bortezomib results in decreased expression of NADK mRNA CTD PMID:20977926 NCBI chr 5:166,145,708...166,176,328
Ensembl chr 5:166,145,481...166,176,322
JBrowse link
G Nadk2 NAD kinase 2, mitochondrial increases expression ISO Bortezomib results in increased expression of NADK2 mRNA CTD PMID:20977926 NCBI chr 2:58,117,674...58,159,815
Ensembl chr 2:58,117,674...58,159,808
JBrowse link
G Naf1 nuclear assembly factor 1 ribonucleoprotein increases expression ISO Bortezomib results in increased expression of NAF1 mRNA CTD PMID:20977926 NCBI chr16:22,837,586...22,868,293
Ensembl chr16:22,837,588...22,868,293
JBrowse link
G Naip6 NLR family, apoptosis inhibitory protein 6 affects expression ISO Bortezomib affects the expression of NAIP mRNA CTD PMID:25913414 NCBI chr 2:31,507,423...31,559,098 JBrowse link
G Nap1l2 nucleosome assembly protein 1-like 2 increases expression ISO Bortezomib results in increased expression of NAP1L2 mRNA CTD PMID:20977926 NCBI chr  X:68,174,051...68,176,449
Ensembl chr  X:68,173,987...68,176,666
JBrowse link
G Ncf4 neutrophil cytosolic factor 4 decreases expression ISO Bortezomib results in decreased expression of NCF4 mRNA CTD PMID:20977926 NCBI chr 7:109,825,420...109,843,389
Ensembl chr 7:109,826,020...109,843,389
JBrowse link
G Nckap1 NCK-associated protein 1 increases expression ISO Bortezomib results in increased expression of NCKAP1 mRNA CTD PMID:20977926 NCBI chr 3:65,417,450...65,491,769
Ensembl chr 3:65,417,453...65,492,217
JBrowse link
G Ncoa3 nuclear receptor coactivator 3 increases expression ISO Bortezomib results in increased expression of NCOA3 mRNA CTD PMID:20977926 NCBI chr 3:154,738,566...154,821,395
Ensembl chr 3:154,738,581...154,818,594
JBrowse link
G Ncr1 natural cytotoxicity triggering receptor 1 decreases expression ISO Bortezomib results in decreased expression of NCR1 protein CTD PMID:19229052 NCBI chr 1:69,614,744...69,622,570 JBrowse link
G Ndrg1 N-myc downstream regulated 1 increases expression ISO Bortezomib results in increased expression of NDRG1 mRNA CTD PMID:20977926 NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880
JBrowse link
G Ndrg3 NDRG family member 3 decreases expression ISO Bortezomib results in decreased expression of NDRG3 mRNA CTD PMID:20977926 NCBI chr 3:145,587,505...145,650,896 JBrowse link
G Nedd1 NEDD1 gamma-tubulin ring complex targeting factor increases expression ISO Bortezomib results in increased expression of NEDD1 mRNA CTD PMID:20977926 NCBI chr 7:27,233,315...27,274,486
Ensembl chr 7:27,233,316...27,274,486
JBrowse link
G Neto2 neuropilin and tolloid like 2 decreases expression ISO Bortezomib results in decreased expression of NETO2 mRNA CTD PMID:20977926 NCBI chr19:21,344,299...21,418,182
Ensembl chr19:21,344,289...21,417,023
JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 increases expression
increases activity
ISO [Bortezomib results in increased expression of NFE2L2 protein] which results in increased expression of CBR3 mRNA; Bortezomib results in increased expression of NFE2L2 protein
Bortezomib results in increased activity of NFE2L2 protein
CTD PMID:20806931 PMID:30818834 NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
JBrowse link
G Nfia nuclear factor I/A decreases expression ISO Bortezomib results in decreased expression of NFIA mRNA CTD PMID:20977926 NCBI chr 5:112,436,655...112,781,878
Ensembl chr 5:112,436,644...112,775,885
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions
decreases expression
ISO [Bortezomib co-treated with vorinostat] results in decreased activity of [NFKB1 protein binds to RELA protein]; [resveratrol co-treated with Bortezomib] results in decreased activity of [RELA protein binds to NFKB1 protein]; Bortezomib inhibits the reaction [belinostat results in increased expression of NFKB1 protein]; Bortezomib inhibits the reaction [romidepsin results in increased expression of NFKB1 protein]; Bortezomib promotes the reaction [Fenretinide inhibits the reaction [TNF protein results in increased activity of NFKB1 protein]]
Bortezomib results in decreased expression of NFKB1 mRNA; Bortezomib results in decreased expression of NFKB1 protein
CTD PMID:12893773 PMID:16230421 PMID:17164350 PMID:17626072 PMID:18223231 More... NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
JBrowse link
G Nfkb2 nuclear factor kappa B subunit 2 decreases cleavage
decreases expression
ISO Bortezomib results in decreased cleavage of NFKB2 protein
Bortezomib results in decreased expression of NFKB2 mRNA; Bortezomib results in decreased expression of NFKB2 protein
CTD PMID:17626072 PMID:18223231 PMID:25913414 NCBI chr 1:245,164,586...245,173,225
Ensembl chr 1:245,165,950...245,173,213
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions
increases phosphorylation
increases stability
increases degradation
increases expression
decreases degradation
ISO 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; [Bortezomib co-treated with Arsenic Trioxide] affects the expression of NFKBIA protein; [Bortezomib co-treated with TNFSF10 protein] inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; [Dexamethasone co-treated with Bortezomib] results in increased expression of NFKBIA mRNA; [Dexamethasone co-treated with Bortezomib] results in increased phosphorylation of NFKBIA protein; alvocidib promotes the reaction [Bortezomib results in increased expression of NFKBIA protein modified form]; Ammonium Chloride inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Bortezomib inhibits the reaction [belinostat results in increased expression of NFKBIA protein]; Bortezomib inhibits the reaction [romidepsin results in increased expression of NFKBIA protein]; Bortezomib promotes the reaction [alvocidib results in increased expression of NFKBIA protein modified form]; Bortezomib results in increased phosphorylation of and results in increased degradation of NFKBIA protein; Chloroquine inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Dexamethasone inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; GSK3B protein mutant form inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; IKBKB protein affects the reaction [Bortezomib results in increased phosphorylation of and results in increased degradation of NFKBIA protein]; MAP1LC3B protein affects the reaction [Bortezomib results in increased phosphorylation of NFKBIA protein]; NFKBIA protein mutant form inhibits the reaction [Bortezomib results in increased expression of PTGS2 protein]; SC 514 affects the reaction [Bortezomib results in increased phosphorylation of NFKBIA protein]; SC 514 inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; Wortmannin inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]
Bortezomib results in increased stability of NFKBIA protein
Bortezomib results in increased expression of NFKBIA mRNA; Bortezomib results in increased expression of NFKBIA protein modified form
Bortezomib results in decreased degradation of NFKBIA protein
CTD PMID:15039284 PMID:15543232 PMID:17895889 PMID:18089816 PMID:18223231 More... NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
JBrowse link
G Nfkbib NFKB inhibitor beta increases stability
increases expression
ISO Bortezomib results in increased stability of NFKBIB protein
Bortezomib results in increased expression of NFKBIB mRNA
CTD PMID:15543232 PMID:20977926 PMID:25913414 NCBI chr 1:84,046,292...84,053,862
Ensembl chr 1:84,046,295...84,053,862
JBrowse link
G Nfkbie NFKB inhibitor epsilon multiple interactions
increases stability
ISO Bortezomib inhibits the reaction [arsenic trioxide results in decreased expression of NFKBIE mRNA]
Bortezomib results in increased stability of NFKBIE protein
CTD PMID:15543232 PMID:20471514 NCBI chr 9:15,443,600...15,450,437
Ensembl chr 9:15,436,941...15,450,437
JBrowse link
G Nfyc nuclear transcription factor Y subunit gamma decreases expression ISO Bortezomib results in decreased expression of NFYC mRNA CTD PMID:20977926 NCBI chr 5:134,336,802...134,405,372
Ensembl chr 5:134,336,808...134,405,377
JBrowse link
G Nipsnap1 nipsnap homolog 1 decreases expression ISO Bortezomib results in decreased expression of NIPSNAP1 mRNA CTD PMID:20977926 NCBI chr14:79,734,234...79,758,101
Ensembl chr14:79,734,209...79,758,098
JBrowse link
G Nlrp12 NLR family, pyrin domain containing 12 multiple interactions
increases expression
ISO Bortezomib promotes the reaction [arsenic trioxide results in increased expression of NLRP12 mRNA]
Bortezomib results in increased expression of NLRP12 mRNA
CTD PMID:20471514 NCBI chr 1:65,932,610...65,969,873
Ensembl chr 1:65,932,595...65,960,934
JBrowse link
G Nlrp3 NLR family, pyrin domain containing 3 decreases expression ISO Bortezomib results in decreased expression of NLRP3 mRNA CTD PMID:17659339 NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
JBrowse link
G Nos1 nitric oxide synthase 1 increases expression
multiple interactions
ISO Bortezomib results in increased expression of NOS1 protein
betulinic acid inhibits the reaction [Bortezomib results in increased expression of NOS1 protein]
CTD PMID:30482226 NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
JBrowse link
G Notch2 notch receptor 2 decreases expression ISO Bortezomib results in decreased expression of NOTCH2 mRNA CTD PMID:20977926 NCBI chr 2:185,610,594...185,744,088
Ensembl chr 2:185,610,589...185,744,088
JBrowse link
G Npm1 nucleophosmin 1 multiple interactions
affects response to substance
increases response to substance
ISO Acetylcysteine inhibits the reaction [NPM1 protein mutant form results in increased susceptibility to Bortezomib]
NPM1 protein affects the susceptibility to Bortezomib
CTD PMID:23877794 NCBI chr10:17,741,512...17,751,626
Ensembl chr10:17,739,941...17,751,645
JBrowse link
G Nptx1 neuronal pentraxin 1 decreases expression ISO Bortezomib results in decreased expression of NPTX1 mRNA CTD PMID:20977926 NCBI chr10:104,811,107...104,820,358
Ensembl chr10:104,811,403...104,820,367
JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 increases expression ISO Bortezomib results in increased expression of NQO1 mRNA CTD PMID:20977926 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
JBrowse link
G Nqo2 N-ribosyldihydronicotinamide:quinone reductase 2 increases expression ISO Bortezomib results in increased expression of NQO2 mRNA CTD PMID:20977926 NCBI chr17:30,909,482...30,938,725
Ensembl chr17:30,909,187...30,938,320
JBrowse link
G Nr1h3 nuclear receptor subfamily 1, group H, member 3 decreases expression ISO Bortezomib results in decreased expression of NR1H3 mRNA CTD PMID:20977926 NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
JBrowse link
G Nr1h4 nuclear receptor subfamily 1, group H, member 4 multiple interactions ISO Bortezomib inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein] CTD PMID:25257666 NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 multiple interactions ISO Bortezomib inhibits the reaction [6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein] CTD PMID:30818834 NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906
JBrowse link
G Nrip3 nuclear receptor interacting protein 3 increases expression EXP Bortezomib results in increased expression of NRIP3 mRNA CTD PMID:20830808 NCBI chr 1:163,789,738...163,815,036
Ensembl chr 1:163,789,738...163,815,600
JBrowse link
G Nt5c2 5'-nucleotidase, cytosolic II increases expression ISO Bortezomib results in increased expression of NT5C2 mRNA CTD PMID:20977926 NCBI chr 1:245,770,993...245,896,925
Ensembl chr 1:245,772,277...245,897,913
JBrowse link
G Nt5e 5' nucleotidase, ecto decreases expression ISO Bortezomib results in decreased expression of NT5E mRNA CTD PMID:20977926 NCBI chr 8:89,271,046...89,314,918
Ensembl chr 8:89,270,696...89,314,881
JBrowse link
G Nub1 negative regulator of ubiquitin-like proteins 1 increases expression ISO Bortezomib results in increased expression of NUB1 mRNA CTD PMID:20977926 NCBI chr 4:10,442,917...10,473,689
Ensembl chr 4:10,442,917...10,473,694
JBrowse link
G Nucks1 nuclear casein kinase and cyclin-dependent kinase substrate 1 decreases expression ISO Bortezomib results in decreased expression of NUCKS1 mRNA CTD PMID:20977926 NCBI chr13:43,345,091...43,374,316
Ensembl chr13:43,345,115...43,370,229
JBrowse link
G Numb NUMB, endocytic adaptor protein increases expression ISO Bortezomib results in increased expression of NUMB mRNA CTD PMID:20977926 NCBI chr 6:103,431,400...103,553,422
Ensembl chr 6:103,431,400...103,553,354
JBrowse link
G Numbl NUMB-like, endocytic adaptor protein increases expression ISO Bortezomib results in increased expression of NUMBL mRNA CTD PMID:20977926 NCBI chr 1:82,549,814...82,573,788
Ensembl chr 1:82,550,054...82,573,776
JBrowse link
G Nupr1 nuclear protein 1, transcriptional regulator multiple interactions
increases expression
ISO NUPR1 mutant form promotes the reaction [Bortezomib results in increased expression of ATF4 mRNA]
Bortezomib results in increased expression of NUPR1 mRNA
CTD PMID:20022965 NCBI chr 1:181,213,292...181,215,327 JBrowse link
G Nxpe3 neurexophilin and PC-esterase domain family, member 3 increases expression ISO Bortezomib results in increased expression of NXPE3 mRNA CTD PMID:20977926 NCBI chr11:44,726,905...44,777,694
Ensembl chr11:44,727,069...44,777,694
JBrowse link
G Obscn obscurin, cytoskeletal calmodulin and titin-interacting RhoGEF decreases expression ISO Bortezomib results in decreased expression of OBSCN mRNA CTD PMID:20977926 NCBI chr10:43,774,113...43,919,718
Ensembl chr10:43,789,293...43,919,723
JBrowse link
G Ogdh oxoglutarate dehydrogenase decreases expression ISO Bortezomib results in decreased expression of OGDH mRNA CTD PMID:20977926 NCBI chr14:81,150,021...81,217,479
Ensembl chr14:81,150,091...81,217,479
JBrowse link
G Ogfr opioid growth factor receptor decreases expression ISO Bortezomib results in decreased expression of OGFR mRNA CTD PMID:20977926 NCBI chr 3:167,703,173...167,709,459
Ensembl chr 3:167,702,695...167,709,473
JBrowse link
G Ogt O-linked N-acetylglucosamine (GlcNAc) transferase decreases expression ISO Bortezomib results in decreased expression of OGT mRNA CTD PMID:20977926 NCBI chr  X:66,771,278...66,816,148
Ensembl chr  X:66,771,349...66,816,146
JBrowse link
G Orai2 ORAI calcium release-activated calcium modulator 2 decreases expression ISO Bortezomib results in decreased expression of ORAI2 mRNA CTD PMID:20977926 NCBI chr12:20,500,308...20,520,428
Ensembl chr12:20,497,317...20,520,428
JBrowse link
G Os9 OS9, endoplasmic reticulum lectin increases expression ISO Bortezomib results in increased expression of OS9 mRNA CTD PMID:20977926 NCBI chr 7:62,915,498...62,957,591
Ensembl chr 7:62,915,515...62,943,745
JBrowse link
G Osbpl2 oxysterol binding protein-like 2 increases expression ISO Bortezomib results in increased expression of OSBPL2 mRNA CTD PMID:20977926 NCBI chr 3:167,210,945...167,256,219
Ensembl chr 3:167,210,832...167,256,219
JBrowse link
G Osgin1 oxidative stress induced growth inhibitor 1 increases expression ISO
EXP
Bortezomib results in increased expression of OSGIN1 mRNA CTD PMID:20830808 PMID:20977926 NCBI chr19:47,471,750...47,500,517
Ensembl chr19:47,492,171...47,500,516
JBrowse link
G Pacsin1 protein kinase C and casein kinase substrate in neurons 1 increases expression ISO Bortezomib results in increased expression of PACSIN1 mRNA CTD PMID:20977926 NCBI chr20:5,718,134...5,768,064
Ensembl chr20:5,719,857...5,765,313
JBrowse link
G Palld palladin, cytoskeletal associated protein increases expression ISO Bortezomib results in increased expression of PALLD mRNA CTD PMID:20977926 NCBI chr16:28,228,006...28,621,349 JBrowse link
G Panx2 pannexin 2 increases expression ISO Bortezomib results in increased expression of PANX2 mRNA CTD PMID:20977926 NCBI chr 7:120,139,259...120,153,056
Ensembl chr 7:120,139,294...120,152,361
JBrowse link
G Papola poly (A) polymerase alpha decreases expression ISO Bortezomib results in decreased expression of PAPOLA mRNA CTD PMID:20977926 NCBI chr 6:124,682,015...124,734,706
Ensembl chr 6:124,682,105...124,734,468
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage
increases expression
ISO [alvocidib co-treated with Bortezomib] results in increased cleavage of PARP1 protein; [Arsenic Trioxide co-treated with Bortezomib] results in increased degradation of PARP1 protein; [Bortezomib co-treated with abexinostat] results in increased activity of PARP1 protein; [Bortezomib co-treated with Butyrates] results in increased degradation of PARP1 protein; [Bortezomib co-treated with Doxorubicin] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with N,N-dimethylsphingosine] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with Sorafenib] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein; [Bortezomib co-treated with trichostatin A] results in increased cleavage of and results in increased activity of PARP1 protein; [Bortezomib co-treated with Vorinostat] results in increased degradation of PARP1 protein; [Bortezomib results in increased susceptibility to and results in increased activity of TNFSF10 protein] which results in increased cleavage of PARP1 protein; [BRCA1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; [Curcumin co-treated with Bortezomib] results in increased cleavage of PARP1 protein; [Dichlororibofuranosylbenzimidazole co-treated with Bortezomib] results in increased cleavage of PARP1 protein; [RB1 mutant form results in increased susceptibility to Bortezomib] which results in increased cleavage of PARP1 protein; AKT1 protein inhibits the reaction [[Bortezomib co-treated with Sorafenib] results in increased cleavage of PARP1 protein]; AKT1 protein inhibits the reaction [[Bortezomib co-treated with TNFSF10 protein] results in increased cleavage of PARP1 protein]; benzyloxycarbonyl-valyl-alanyl-aspartic acid analog inhibits the reaction [Bortezomib promotes the reaction [gambogic acid results in increased cleavage of PA